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ABSTRACT 
 
Cardiovascular diseases are the leading causes of mortality in the United States 
and will cost around $500 billion this year alone. Elevated proteolytic activity, increased 
proliferation and migration of vascular smooth muscle cells are hallmarks of 
atherosclerosis, stenosis and aortic aneurysms. These diseases often manifest the 
transdifferentiation of vascular smooth muscle cells into osteoblast-like cells followed by 
deposition of hydroxyapatite-like mineral in the arterial walls.   
Currently, there are no standard treatments available for vascular calcification or 
aneurysms. Atherosclerosis treatment options are limited to statins while balloon 
angioplasty and stenting – surgical procedures for stenosis, often end in restenosis. 
Therefore, we investigated pentagalloylglucose (PGG), a polyphenolic compound, as a 
therapeutic agent that can inhibit excess proteolytic activity, mitigate proliferation and 
disrupt the transformation of vascular smooth muscle cells into osteoblast-like cells. 
Previous experiments conducted in our lab have shown that PGG has elastoprotective 
properties in a rat aneurismal model. Studies conducted by other researchers have shown 
that PGG also has anti-cancer and anti-inflammatory properties.   
Our results show that PGG effectively decreased the level of cathepsins K, L and 
S, and the activity of MMP-2 in tumor necrosis factor activated rat aortic smooth muscle 
cells (RASMCs) in vitro. Transcription levels of cathepsins K and S were dramatically 
decreased by PGG. Scratch test assay showed that PGG treatment resulted in visibly 
reduced migration and proliferation. PGG treatment also reduced the expression of 
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osteogenic markers in activated RASMCs. Gene expressions of CBFA-1 and MSX-2 
were downregulated. Alkaline phosphatase activity was significantly reduced at days 1, 3 
and 6. Addition of PGG 3 days past activation of RASMCs also resulted in decreased 
alkaline phosphatase activity, signifying that PGG could potentially reverse osteogenic 
differentiation of RASMCs. 
We also conducted studies to verify if PGG could possibly increase elastin 
production in primary RASMCs by potentially inhibiting proteolytic activity. We found 
that levels of both tropoelastin and insoluble elastin were significantly increased in cells 
treated with PGG.  
In order to deliver PGG locally to a diseased vascular site, we investigated the 
possibility of using nanoparticles. Poly(lactic-co-glycolic acid) nanoparticles 
encapsulated with PGG were prepared and their in vitro release profiles were studied. 
Sonication times during emulsion steps were varied and resulting encapsulation 
efficiencies were studied. 
We conclude that PGG could potentially be a valuable therapeutic agent in 
vascular pathologies. Excess proteolytic activity, migration and proliferation of RASMCs 
were effectively controlled by PGG. PGG also inhibited the osteogenic signaling in 
smooth muscle cells through potentially affecting cell cycle progression by down 
regulating the gene expression of c-Fos. PGG could be used alone or with other existing 
treatments to control or reverse vascular diseases discussed above. Further optimization 
needs to be performed in order to determine the dose and mode of PGG delivery in vivo. 
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CHAPTER 1  
INTRODUCTION 
Cardiovascular diseases are the leading cause of mortality in many developed 
countries including the United States. In 2006 alone, cardiovascular diseases accounted 
for 34.3% of all deaths in the United States. The total cost of cardiovascular disease and 
stroke in the United States for 2010 is estimated to be $503.2 billion.
1
  
Hypercholesterolemia, hypertension, smoking, aging, genetic predisposition and diabetes 
mellitus are considered risk factors for atherosclerosis.
2
 Cardiovascular diseases include 
atherosclerosis – deposition of fatty acids, stenosis – blockage of the arterial lumen, 
aneurysm – dilation of the aortic vessel and vascular calcification – ectopic 
mineralization of arterial tissue. All these pathological conditions involve a number of 
proteins, transcription factors and multiple cellular pathways. Controlling these diseases 
is important to prevent cardiac infarction, stroke or even death. Inhibitors of proteolytic 
enzymes are currently being studied extensively as potential therapeutic agents in many 
diseases.  
Polyphenols are plant derived metabolites that contain multiple phenol groups. 
Polyphenols derived from tea and spices have shown to be effective at inhibiting 
proteolytic enzymes in vitro.
83
 Pentagalloylglucose (PGG) is a polyphenol with a 
structure very similar to that of tannic acid. Previously in our lab, studies have shown that 
PGG successfully inhibited the degradation of elastin in a rat aneurysm model.  
 2 
This research is focused on three pathological processes namely extracellular 
matrix degradation, calcification and smooth muscle cell proliferation. We hypothesize 
that all these three events are interrelated and PGG can arrest all these pathological 
processes. 
1.1. AIM 1 
Characterization of the anti-proteolytic and anti-proliferative activities of 
pentagalloylglucose in tumor necrosis factor activated rat aortic smooth muscle cells 
Hypothesis 
Primary rat aortic smooth muscle cells activated with tumor necrosis factor alpha 
produce excess proteolytic enzymes and undergo excess proliferation. This process is 
similar to pathological conditions observed in inflammatory clinical conditions. 
Pentagalloylglucose inhibits the activity of proteolytic enzymes and decreases 
proliferation of the activated cells.  
1.2. AIM 2 
Characterization of elastic fiber assembly by primary smooth muscle cells treated 
with pentagalloylglucose. 
Hypothesis 
 
Pentagalloylglucose increases the level of released tropoelastin and deposited 
insoluble elastin by inhibiting their proteolytic degradation. Pentagalloylglucose could 
also bind to the hydrophobic domains in tropoelastin making it more resistant to 
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elastases. Both these effects lead to increased extracellular assembly of mature elastic 
fibers. 
1.3. AIM 3 
Characterization of pentagalloylglucose induced anti-osteogenic differentiation of 
tumor necrosis factor activated rat aortic smooth muscle cells  
Hypothesis 
 
Pentagalloylglucose inhibits the dedifferentiation of activated rat aortic smooth 
muscle cells and prevents them from transforming into osteoblast-like cells. In parallel, 
pentagalloylglucose increases the calcium deposition by osteoblasts 
1.4. AIM 4 
Preparation and characterization of poly-(lactic-co-glycolic) acid nanoparticles 
encapsulating pentagalloylglucose that could potentially be used for local delivery of 
pentagalloylglucose in vivo 
Hypothesis 
 
Pentagalloylglucose can be encapsulated in polymeric nanoparticles. These 
nanoparticles can potentially be delivered to the vascular site and inhibit proteolytic 
activity locally. This process may aid in reducing the degradation of existing elastin and 
allow the deposition of insoluble elastin in animal models of aortic aneurysms and medial 
calcification.  
 4 
1.5. AIM 5 
Implementation and preliminary characterization of a new in vitro model of 
medial vascular calcification using cryo-sectioned arterial scaffolds 
Hypothesis 
Arteries cryo-sectioned perpendicular to the cross section can be used to line the 
bottom of well plates and create a scaffold for cells that mimics extracellular matrix in 
the medial layer of the artery. Interactions between vascular smooth muscle cells and the 
extracellular matrix in the medial layer can be studied using this model. 
 5 
 
CHAPTER 2  
LITERATURE REVIEW 
2.1. VASCULAR ARCHITECTURE 
The heart and the elastic arteries transport blood from the heart to the whole body. 
The large/elastic arterial wall consists of three layers – inner ‘intima’, ‘media’ and outer 
‘adventita’. Intima is made of a thin lining of endothelium, its basal lamina and an elastic 
layer called internal elastic membrane. Endothelium contains simple squamous epithelial 
cells oriented in the direction of blood flow. These epithelial cells are connected to one 
another by tight gap junctions. The endothelium and the basal lamina control diffusion of 
most substances to the arterial walls. 
Media of the elastic arteries is relatively thicker and has a different composition. 
This layer has sheets (lamellae) of elastic material interspersed with smooth muscle cell 
layers. The concentric elastin lamellae have fenestrations which are believed to help in 
diffusion of substances through the arterial wall. The smooth muscle cells are arranged in 
a spiral and interconnected by gap junctions. They synthesize the connective tissue 
proteins – elastin and collagen. Adventitia mainly consists of connective tissue and is 
usually thinner than media. The main structural protein is collagen along with a loose 
mesh of elastic fibers. Fibroblasts and macrophages are present in this layer. Tiny blood 
vessels called ‘vasa vasorum’ supply blood to the adventitia and outer portions of the 
media. Inner layers of the arterial wall are vascularized with the lumen. 
 6 
 
Figure 2.1: Morphology of a normal artery 
3
 
The large arteries, along with the heart, help maintain a pulsate flow of blood. 
During systole, the ventricles contract, causing the blood to flow through the elastic 
arteries. The pressure generated by the ventricles causes the distention of the elastic 
arteries which is opposed by the collagen fibers. The elastic tension built by the arteries is 
released and used to ‘pump’ the blood during diastole. This results in a synchronous 
pulsating of the arteries in response to the systole and diastole phases. This feature of the 
elastic arteries to behave as a supplementary pump is critical in maintaining blood 
pressure.
4
 
2.2. VASCULAR PATHOLOGY 
Cardiovascular disease is the leading cause of mortality in the United States. 
Mortality data for 2006 shows that cardiovascular disease caused for 34.3% of all deaths 
in 2006 in the United States. The total direct and indirect cost of cardiovascular disease 
and stroke in the United States for 2010 is estimated to be $503.2 billion.
1
 
Hypercholesterolemia, hypertension, smoking, aging, male gender and diabetes mellitus 
 7 
are considered risk factors for atherosclerosis while a high ratio of high density 
lipoprotein (HDL) to low density lipoprotein (LDL) is considered beneficial for 
cardiovascular health.
2
 Constant fluid flow causes shear stress and normal 
(perpendicular) stress results in cyclic strain of the arterial wall. With the progression of 
age, the constant stresses, combined with numerous factors such as inflammation and 
lipid deposition, results in many pathological conditions like hypertension, 
atherosclerosis, stenosis, medial calcification and aneurysm. These conditions are 
associated with several serious events like cardiac myofarction, thromboembolism and 
even death.
4
 
2.3. ATHEROSCLEROSIS 
Atherosclerosis is an inflammatory disease of the luminal surface of large and 
medium sized arteries. Aorta, carotid arteries, coronary arteries and the arteries of the 
lower extremities are affected by this disease.
5
 Atherosclerotic lesions can begin to 
appear at childhood but can take decades before the pathological effects can be felt. The 
full-fledged atherosclerotic plaque is characterized by a large core made of necrotic fatty 
mass covered with a thin fibrous cap made of mostly collagen. Since atherosclerosis 
develops over a long period of time, initial cause for the development of plaque has been 
a subject of study. One of the most popular hypotheses is the ‘response-to-injury model’ 
which suggests that the endothelial layer is injured in some way leading to the 
advancement of atherosclerosis. Although it was first proposed in the mid nineteenth 
century, it is still widely accepted as a possible explanation. Chemical, mechanical or 
immunological insults that can cause endothelial dysfunction can lead to lipoproteins, 
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free radicals and toxic substances migrating to the sub-endothelial space.
3
 Infectious 
agents including herpes virus and Chlamydia pneumonia are also considered possible 
causative agents.
6
 Earlier sign of atherosclerosis is the appearance of yellowish, flat ‘fatty 
streak’ which is an accumulation of neointimal lipids, and is non-obstructive. ‘Fibrous 
plaque’ is found later in life, after the second or third decade, characterized by a more 
pronounced whitish lesion. At this stage, plaque contains infiltrating macrophages and 
other inflammatory cells, proliferating smooth muscle cells and deposited extracellular 
matrix proteins. On the interior of the fibrous plaque is a ‘necrotic/lipid core’ that 
contains foam cells, extracellular lipid, and cell debris. The fibrous plaques are capable of 
interrupting blood flow and can cause flow distortions in blood vessels. However, the 
surface of the plaque is stable and does not contain thrombotic material. It is unclear 
whether the fatty streak leads to the fibrous plaque or the latter can form de novo.
3
 The 
plaque can lead to vascular remodeling, abnormalities in blood flow dynamics, partial or 
complete obstruction of blood flow many of which can lead to ischemia, decreased 
oxygen supply, to critical organs. These secondary conditions cause a positive feedback 
cycle leading to advancement of artery disease.
3
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2.4. VASCULAR CALCIFICATION 
The presence of calcium deposits in the vessel wall is indicative of advanced 
atherosclerosis, and has been found to increase risk factors for coronary artery disease.
7, 8
 
With advanced age, vascular calcification causes a reduction in elasticity of the vessel 
wall. In high-risk asymptomatic adults the presence of calcification has been shown to 
increase the risk of a coronary death or nonfatal infarction.
9
 Vascular calcification has 
been classified to be of four types based on the histological and anatomical perspectives 
by Vattikuti et al (2004) as (1) Atherosclerotic calcification (2) Medial calcification (3) 
Cardiac valve calcification and (4) Calciphylaxis.
10
 Vascular calcification is present in 
80% of advanced lesions and 90% of coronary artery disease.
11
 Calcification in the 
plaque can complicate the situation due to risk of ulceration at the luminal surface, and 
hemorrhage from small vessels that grow into the lesion from the media of the blood 
vessel wall. Though advanced lesions can grow sufficiently large to block blood flow, the 
most important clinical complication is a severe occlusion due to the formation of a 
thrombus or blood clot, resulting in myocardial infarction or stroke. Furthermore, there is 
the risk of plaque rupture leading to thrombosis.
12
 Considerable research in the past few 
years points to remarkable similarities between vascular calcification and bone 
ossification. This review will outline some of these similarities including the association 
of bone diseases like osteoporosis with pathological calcification of arteries. Recently, 
cells, proteins, and cytokines known to be involved in new bone formation have been 
observed atherosclerotic arteries. The increased expression of various bone-related 
proteins in atherosclerotic plaque, especially in areas of calcification has led to the 
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observation that arterial calcification is similar to the mechanism of new bone 
formation.
13-16
 In order to highlight some of the parallels between arterial calcification 
and bone mineralization, we will review main aspects of bone physiology and then 
compare them to arterial calcification.  
2.5. BONE PHYSIOLOGY – IMPORTANT MOLECULAR AND GENETIC ASPECTS 
The skeletal system is a store for important minerals like calcium and magnesium. 
Thus, bone remodeling is a function of both mechanical stresses (Wolff’s law) and the 
mineral ion requirements of the body. The homeostatic balance of the various mineral 
ions in the body is maintained by numerous hormones, genetic factors and environmental 
conditions. Osteoblasts are bone forming cells derived from mesenchymal progenitors. 
Osteoblasts lay down the mineralizable collagen matrix and are also involved in the 
ossification stage. Osteoclasts, derived from hematopoietic (mononuclear phagocyte) 
precursors, are responsible for degradation/resorption of bone and help maintain a 
homeostatic balance of mineral ions and aid in the repair and maintenance of skeletal 
structure. Both osteoblasts and osteoclasts are coupled in many ways and thus it is 
extremely difficult to alter one without affecting the other.  
2.6. ROLE OF CYTOKINES AND GENETIC ASPECTS OF SKELETAL TISSUE 
The structure of the skeleton in vertebrates is determined by complex signaling 
systems of various genes during and after embryogenesis. Most long bones develop by 
endochondral ossification that involves formation of a cartilage model, chondrocyte 
apoptosis and replacement of cartilage by mineralized bone. Flat bones, like the 
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craniofacial bones, are formed by intramembranous ossification in which bone is made 
directly by osteoblasts without a cartilaginous intermediate. During both types of 
ossification, there are a number of local growth factors, hormones, and genetic factors 
which influence and synchronize the events.
17
 Pluripotent mesenchymal stem cells are 
capable of differentiation into adipocytes, myoblasts, chondrocytes, or osteoblasts. 
Commitment towards a particular lineage depends upon coordinated expression of sets of 
specific transcription factors and simultaneous suppression of other genetic programs that 
specify alternative cellular fates. As seen from the diagram, the main transcription factors 
responsible for the differentiation of mesenchymal stem cells into osteoblasts are Runx2 
(also called core binding factor alpha -1 or cbfa-1) and Osx (osterix). Mice with targeted 
deletion of the gene encoding Cbfa1/Runx2 exhibit a complete lack of osteoblasts and die 
soon after birth.
18, 19
 Distal-less5 (Dlx5), CBFA-1, and osterix (Osx) are transcription 
factors that are believed to be absolutely essential for differentiation of pluripotent 
mesenchymal progenitors into terminally differentiated osteoblasts.
20
 CBFA-1 (also 
called Runx2) plays an important role in the terminal differentiation as well as 
functioning of osteoblasts. CBFA-1 has been known to induce collagen I, osteocalcin, 
and alkaline phosphatase gene expressions in osteoblasts.
21, 22
 Muscle segment homeobox 
2 (Msx-2) is a homeodomain transcription factor important for osteoblast differentiation 
and a downstream target of BMP signaling.
23
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2.7. THEORIES OF VASCULAR CALCIFICATION 
There are several models to explain the process of vascular calcification and 
although none of the models can fully explain the pathological conditions associated with 
the disease, the models can be classified under the following categories:  
1. Passive physiochemical models 
2. Active cell mediated models 
Passive physicochemical models of vascular calcification 
This model affirms that vascular calcification is mainly due to of acellular 
mechanisms, and is governed by biochemical relationships. A charge neutralization 
theory proposed by D. W. Urry et al in 1971 suggests that elastin and collagen contain 
‘neutral sites’ which have affinity for calcium ions.24 Molecules such as alpha 2-HS 
glycoproteins (AHSGs) are active inhibitors of calcification in serum. AHSGs are 
ubiquitous, highly abundant in serum and bind to calcium efficiently preventing 
calcinosis or blockage of small blood vessels. AHSG-deficient mice with normal calcium 
ion levels develop sporadic perivascular calcification while hypercalcemic mice (induced 
by dietary means or by hormone treatment) die of lethal calcinosis.
25
 Disphosphonates, 
proteoglycans (found in cartilage), magnesium & aluminum ions, serum proteins, metal-
citrate complexes, and acidic proline-rich phosphoproteins suppress the growth of 
hydroxyapatite in various tissues and act as crystallization inhibitors.
26
 Other studies 
claim that the phosphate group is responsible for the nucleation of calcium phosphate by 
means of the phosphoprotein complex and collagen.
27
 Matrix vesicles have also been 
found to initiate calcification in atherosclerotic arteries.
28,29, 30
 Matrix vesicles can induce 
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mineralization by compartmentalizing mineral ions and cause selective enrichment of 
specific proteins, enzymes, lipids and electrolytes. Rapid uptake of mineral ions by 
matrix vesicles leads to the crystalline phase, octacalcium phosphate (OCP) which is later 
converted to hydroxyapatite. Initial uptake of Calcium and phosphate ions by the matrix 
vesicles is protease sensitive, and is stimulated by o-phenanthroline, a Zinc ion chelator.
31
 
It has been observed that lipid molecules have been strongly associated with the initiation 
of matrix vesicle calcification.
32
 This is very relevant to arterial calcification during 
atherosclerosis. Furthermore, Even though matrix vesicles essentially bud off from cells, 
almost all studies consider these vesicles to be more biochemical than cell-mediated. 
Although passive models of atherosclerotic calcification emphasize on the biological 
molecules being the main molecules involved in the pathology, they do not mention the 
involvement or relative importance of cells which secrete these molecules.  
2.8. ACTIVE, CELL-MEDIATED MODELS OF VASCULAR CALCIFICATION 
Arterial calcification began to be considered as an active process involving many 
cell types after the observations by Bostrom et al (1993) in which a division of the 
cultured vascular cells calcified and were named ‘Calcifying vascular cells’ or CVCs. 
These CVCs were distinct from the other vascular cells as they localized along with the 
expression of bone related proteins like BMP-2.
33, 34
 Later, it was noticed that cultured 
vascular smooth muscle cells could also undergo spontaneous calcification in vitro and 
form mineralized nodules under certain conditions and express matrix proteins typically 
found in bone.
35, 36
 Moreover, bone matrix-associated proteins appears to be expressed in 
a number of cell types in arterial tissue sections and thus the precise identification of the 
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CVCs in arterial calcification in vivo remains uncertain.
37, 38
 Human and animal studies of 
atherosclerosis have shown the existence of cells that are phenotypically similar to the 
major cell types found in bone remodeling – osteoblasts, osteoclasts and chondroblasts. 
Endochondral ossification has also been observed in diseased arteries with the process 
indistinguishable from that of bone tissue.
38-41
 Additionally, signaling pathways 
corresponding to those in bone were found in these calcifying cells.
14, 42
 Similar to bone 
mineralization, arterial tissues also undergo mineralization through matrix vesicles.
29
 The 
mineral composition of bone is chemically very similar to that found in calcified 
atherosclerotic plaques.
43
 Thus, arterial calcification resembles bone mineralization very 
closely. 
In the active model, the emphasis is on the phenotypes or change in phenotypes of 
various cell types in atherosclerotic arteries while very little importance is given to the 
actual chemical environment. However vascular calcification in vivo can be a 
combination of both models in varying degrees.  
2.9. BONE RELATED PROTEINS AND THEIR ROLE IN VASCULAR CALCIFICATION 
Various bone matrix regulatory proteins have been upregulated in atherosclerotic 
aortas. Diseased aortas demonstrated calcification of the plaques and up-regulation of 
BMP-2, BMP-4, osteopontin, osteocalcin, matrix Gla protein and bone sialoprotein 
compared to the healthy aortas. All these are markers of osteoblast differentiation or, in 
other words, bone formation.
43
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Figure 2.2: Proposed role of BMP2/MSX-2 in vascular calcification 
44 
 
2.10. VASCULAR CALCIFICATION AND OSTEOPOROSIS 
Presence of atherosclerosis and vascular calcification is often observed with 
osteoporosis and vice versa. It has been shown that women with vascular calcification 
have a higher risk of suffering fractures, a sign of osteoporosis. Indeed, the risk of 
fractures increased with the amount of vascular calcification.
44
 Aging, estrogen 
deficiency, autoimmune disease, and lipid oxidation are some of the common risk factors 
for both diseases.
45, 46
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Interestingly, atherosclerotic calcification and bone loss in postmenopausal 
women happen almost concurrently leading to simultaneous deposition of calcium in 
vessels while loss of bone.
45, 46
 Osteoprotegerin (OPG), receptor activator for nuclear 
factor κ β (RANK) and receptor activator for nuclear factor κ β ligand (RANKL) forma 
an important triad in the relationship between osteoblasts and osteoclasts in bone as 
shown in Figure 2.3. OPG has in fact hypothesized to be the key common factor between 
the two pathologies. Nevertheless, unlike the skeletal system, the exact mechanism of 
OPG/RANK/RANKL in vascular calcification has not been thoroughly analyzed yet. 
Therapies used for bone loss like bisphosphonates, OPG have also shown to prevent 
arterial calcification in animals.
47, 48
 
 
 
Figure 2.3: Relationship between OPG/RANK/RANKL in bone metabolism
49
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2.11. AORTIC ANEURYSMS 
Abdominal aortic aneurysm (AAA) is often a fatal disease that largely affects 
older patients, accounting for at least 15,000 deaths in the year 2000. Aneurysm can be 
defined as a permanent local dilation of an artery to 150% of its normal diameter.
50
 
Progression of an aneurysm can lead to increased dilation, rupture and death. Aneurysms 
that occur in the cerebral arteries, called cerebral aneurysms, can cause stroke due to 
rupture, and even death. Most abdominal aortic aneurysms are asymptomatic and can 
thus go undetected. Early detection and monitoring are very important to implement 
changes in lifestyle and schedule surgery if necessary.  
The main factor in the initiation and progression of AAA involves the proteolytic 
degradation of extracellular matrix proteins. Degradation of elastin and collagen, two 
main structural proteins of the artery, leads to weakening of the arterial wall, dilation and 
rupture. A range of proteolytic enzymes, including matrix metalloproteases (MMPs) play 
a very important role in degrading collagen and elastin and can lead to remodeling of the 
arterial wall, causing structural weakness. Factors such as cigarette smoking, increased 
oxidative stress and autoimmune conditions can increase risk factors for aneurysms. 
Increased stress on the arterial wall due to high blood pressure could also increase the 
risk of aneurysms, causing disordered flow.
51
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2.12. MATRIX METALLOPROTEINASES 
MMPs are a family of about 25 endopeptidases that require zinc as co-factor. 
MMPs are secreted as inactive zymogens and are activated by cleavage of the pro 
domain. As the name suggests, MMPs degrade extracellular matrix proteins such as 
collagen and elastin. As shown in Table 2.1, members of the MMP family of proteases 
degrade various extracellular matrix proteins. In addition, MMPs play an important role 
in cell-cell and cell-matrix interactions. Several MT-MMPs (membrane type MMPs), 
MMP-2 among a few are expressed by healthy cells. Activated cells release more types 
and quantities of MMPs.
52
Similar to other proteases, MMPs are regulated at (1) 
Transcriptional level (2) Compartmentalization (3) Enzyme activation and (4) Enzyme 
inhibition. Tissue inhibitors of metalloproteinases are a group of four proteins that inhibit 
the activity of MMPs. TIMPs can bind to the active site of MMPs and inhibit their 
proteolytic activity. Some TIMPs are required for activation of some MMPs. Alpha-
2macroglobulin is another MMP inhibitor that is found in the serum.
53
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Table 2.1: Mammalian matrix metalloproteinases 
52
 
MMPs are known to be expressed by atherosclerotic arteries while they are absent 
in healthy arteries.
54
 Activated monocytes in an atherosclerotic plaque can release several 
cytokines and MMPs that degrade the extracellular matrix.
55
 Calcification of elastin has 
also observed to be an important factor in atherosclerosis and is associated strongly with 
MMP activity.
56, 57
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2.13. CATHEPSINS 
Cathepsins are lysosomal cysteine proteases that are mainly involved in 
intracellular protein turnover. There are 11 known cathepsins which are primarily 
involved in non-specific protein degradation within the lysosomes. Most cathepsins 
function in an acidic environment and exhibit reduced activity at higher pH with the 
exception of cathepsin S, which has optimal activity at pH 7.4. In pathological 
conditions, cathepsins are released into the extracellular space where they degrade 
extracellular matrix proteins.
58, 59
 Cathepsin K was first isolated from rabbit osteoclasts. It 
is considered marker of osteoclasts since its proteolytic activity is critical for osteoclast 
bone resorption. Inactive cathepsin K results in a genetic bone disorder called 
pycnodysostosis characterized by abnormal bone resorption.
60-64
 Cathepsin L is found in 
most mammalian cells. It mainly functions in normal protein turnover within lysosomes. 
Cathepsin L has also been implicated in pathological conditions such as excess bone 
resorption, tumor metastases and arthritis.
65-67
 Cathepsin S is a lysosomal enzyme that is 
a highly potent elastase. It has been implicated in Alzheimer’s disease and emphysema.67 
Spleen cells and antigen presenting cells such as B lymphocytes and macrophages 
express high levels of cathepsin S.
68-70
 
2.14. ROLE OF TUMOR NECROSIS FACTOR-ALPHA IN ATHEROSCLEROSIS, VASCULAR 
CALCIFICATION AND ANEURYSMS 
Atherosclerosis, intimal calcification and aneurysms are closely associated with 
inflammatory conditions. Inflammatory cells such as macrophages/ 
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lymphocytes/neutrophils infiltrate into amounts of calcium and phosphorus in chronic 
kidney disease (CKD) patients compared to non-renal patients. In diabetic patients, 
glucose loading causes an increase in serum levels of TNFα.71 Bone markers including 
bone morphogenetic protein -2 (BMP-2), bone sialo-protein, core binding factor alpha-1 
(CBFA-1) were found in significantly higher amounts in CKD patients, even in non-
calcified regions.  Expression of TNFα and Msx-2 (muscle segment homeobox-2) were 
also upregulated along with increased osteoblastic differentiation of aortic smooth muscle 
cells in CKD patients.
72
 Aortic calcification in diabetes and chronic kidney disease have 
common factors including low-grade arterial inflammation, and increased TNFα levels. 
Infliximab, a TNFα neutralizing antibody can diminish the aortic calcification through 
BMP-2-Msx-2-Wnt3a and Wnt7a signaling. In low density lipoprotein receptor knockout 
(LDLr-/-) mice (a model of hypercholesterolemia) fed with high fat diet, infliximab did 
not reduce obesity, hypercholesterolemia, or hyperglycemia but decreased BMP2, Msx-2, 
Wnt3a, and Wnt7a and decreased aortic calcium. Thus TNFα has an important role in 
diabetic and CKD related vascular calcification.
73, 74
 
In vascular smooth muscle cells, TNFα increased the expression of CBFA-1, 
osterix, alkaline phosphatase, bone sialoprotein, all markers of osteogenic differentiation. 
Msx-2 expression was increased in these cells by TNFα through the nuclear factor kappa 
B (NF-κB), in a dose and time dependent manner. TNFα causes the osteogenic 
transdifferentiation through Msx-2 as demonstrated by increased alkaline phosphatase 
expression by over expression of Msx-2 and vice versa due to knockdown of Msx-2 by 
siRNA.
75
 Vascular smooth muscle cells treated with TNFα and phosphate (Pi) showed 
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significant release of many pro-inflammatory cytokines, including tumor necrosis factor 
alpha (TNFα).76 TNFα also causes the release of other cytokines and proteases. Vascular 
smooth muscle cells treated with TNFα showed enhance expression and activity of 
alkaline phosphatase, an osteoblast marker and increased calcium deposition. TNFα 
causes osteogenic differentiation through the cyclic adenosine monophosphate (cAMP) 
pathway as demonstrated by higher levels of intracellular cAMP and its inhibition by a 
protein kinase-A inhibitor.
77
 Alpha-tocopherol (Vitamin E) has been evaluated for 
effectiveness against cardiovascular diseases in many studies. A novel tocopheryl 
phosphate mixture reduced pro-inflammatory markers in atherosclerosis including 
interleukin-1beta (IL-1beta), IL-8, TNFα and reduced lesion development.78 In a study 
conducted with patients with aortic stiffness related to atherosclerosis, anti-TNF-alpha 
therapy improved aortic stiffness compared to untreated patients.
79
 These studies confirm 
the importance of TNFα in vascular pathologies and the potential of inhibiting TNFα and 
its downstream effects. 
2.15. POLYPHENOLS 
Polyphenols are micronutrients found abundantly in plant food sources and have 
become the topic of research in the past 15 years, mainly due to the discovery of their 
antioxidant properties. Plants produce polyphenols as secondary metabolites as a defense 
mechanism against ultraviolet radiation or pathogens. Polyphenols can be classified 
based on the number of phenol rings and structural elements between the phenolic rings 
as: phenolic acids, flavonoids, stilbenes and lignans as shown in Figure 2.4.
80
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Figure 2.4: Types of polyphenols 
80
  
Phenolic acids are further classified as derivatives of benzoic acids or derivatives 
of cinnamic acids.
80
 Structure of flavonoids consists of two aromatic rings (A and B) 
bound together by three carbon atoms that comprise an oxygenated heterocycle (ring C). 
Flavonoids are categorized into 6 subclasses based on type of heterocycle involved: 
flavones, isoflavones, flavanones, anthocyanidins, and flavanols (catechins and 
proanthocyanidins) as shown in Figure 2.5.
80
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Figure 2.5: Types of flavonoids 
80
  
Polyphenols have been shown to have various beneficial effects on health as 
outline in many recent reviews. The benefits include anti-inflammatory, anti-cancer and 
antioxidant effects.
81-85
 Polyphenols also known to down-regulate expression of pro-
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inflammatory mediators, matrix metalloproteinases, and adhesion molecules.
86
 
Polyphenols affect multiple pathways in cells as shown in Figure 2.6.  
 
 
Figure 2.6: Polyphenol has various anti-inflammatory effects 
87
 
Polyphenols act as antioxidants in vitro by scavenge oxidative stress agents or 
additionally by inhibiting oxidative stress induced NF-κB, activator protein-1 (AP-1), 
oxidative stress inducing enzymes such as nitric oxide synthase, and xanthine oxidase. 
Antioxidant activities of polyphenols have been demonstrated more definitively in vitro 
than in vivo.
88
 Turmeric contains a polyphenols called curcumin that can act as an 
antioxidant and modulate important signaling pathways mediated through NF-kappaB 
and mitogen-activated protein kinase pathways.
86
 Epigallocatechin-3-O-gallate (EGCG) 
an anti-oxidant found in green tea is believed to have anti-inflammatory properties. In a 
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study conducted on EGCG treated human umbilical vein endothelial cells (HUVECs), the 
cells exhibited lower monocyte adhesion due to TNFα.89 EGCG also inhibits ultraviolet B 
induced AP-1 and NF-κB-dependent transcriptional activation.90 Pentagalloylglucose 
(PGG) is a polyphenol with a structure as shown in Figure 2.7. PGG has five gallic acid 
residues (structure shown in Figure 2.8) attached to a glucose core.
91
 PGG has been 
investigated by various researchers to have anti-proteolytic, anti-cancer and antioxidant 
properties.  
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Figure 2.7: Structure of pentagalloylglucose 
91
 
 
Figure 2.8: Gallic acid structure 
91
 
Pentagalloylglucose was effective in scavenging free radical 1,1-diphenyl-2-
picrylhydrazyl (DPPH) and protect against lipid peroxidation in leukemia cell line treated 
with hydrogen peroxide. Gallic acid induced the expression of multiple antioxidant 
enzyme genes.
92
 PGG has shown promise as an anti-cancer agent in many studies. PGG 
suppresses the growth of prostate cancer xenografts in nude mice and induces apoptosis 
in prostate cancer cell line and could be used as a potential cancer therapeutic drug.
93
 
PGG inhibits estrogen receptor function and suppressed the growth of estrogen-
responsive human breast cancer cells. Estrogen receptor alpha levels were decreased by 
PGG through degradation in lysosomes.
94
 PGG induces cell cycle arrest at G1 phase 
through downregulation of cyclin-dependent kinases 2 & 4, and upregulation of cyclin-
dependent kinase inhibitors p27 & p21 in human breast cancer cells. In addition to 
inducing apoptosis in human leukemic cells, PGG also has inhibitory effects on 26s 
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proteasomes in Jurkat T cells. PGG affects cell cycles in human leukemic cells through 
its action as a proteasome inhibitor.
95
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CHAPTER 3  
CHARACTERIZATION OF ANTI-PROTEOLYTIC AND ANTI-
PROLIFERATIVE ACTIVITIES OF PENTAGALLOYLGLUCOSE IN TUMOR 
NECROSIS FACTOR ACTIVATED RAT AORTIC SMOOTH MUSCLE CELLS  
3.1. INTRODUCTION 
Mechanical strength and healthy function of the arteries depends on the integrity 
of elastin and collagen. Increased proteolytic activity is a hallmark of many diseases 
including atherosclerosis, aneurysms, stenosis and vascular calcification. Excess release 
of proteases results in indiscriminate degradation of extracellular matrix proteins 
particularly, elastin and collagen.
96-100
 It is therefore important to inhibit excess 
proteolytic activity to control disease progression and preserve the mechanical properties 
of arteries. 
Major classes of proteolytic enzymes that are shown to be activated in vascular 
diseases are matrix metalloproteinases (MMPs) and cathepsins. MMPs are a family of 
enzymes that participate in various cellular functions and degrade extracellular matrix 
proteins.
52
 MMP-2 and MMP-9 are potent collagenases that are important in vascular 
diseases.
96-100
 
Cathepsins are lysosomal cysteine proteases that can be released extracellularly 
during pathological conditions. Cathepsin K is a strong collagenase while cathepsin S is a 
potent elastase. Cathepsins K, L and S are upregulated in multiple vascular pathologies. 
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101-103
 Healthy medial vascular smooth muscle cells (VSMCs) are generally found in the 
media and exist in a contractile state.  Changes that cause the phenotypic transition of 
VSMCs into a synthetic state occur concurrently with extracellular matrix degradation. 
Narrowing of the arterial lumen (stenosis) involves the migration of these synthetic 
VMSCs into the subendothelial layer. Subsequently, the VSMCs proliferate and deposit 
additional extracellular matrix causes the lumen to occlude, which results in stenosis. 
Surgical procedures such as balloon angioplasty or stenting can expand the luminal 
diameter but are usually followed by restenosis.
104,105
 Polyphenolic compounds have 
shown to be beneficial in inhibiting the activity of proteolytic enzymes in multiple 
studies.
106-108
 Pentagalloylglucose (PGG) has been used in previous studies in our lab and 
proven to be elastoprotective in a rat model of aneurysm.
109,110
 In these studies, we 
studied the effects of PGG on the proteolytic activity, proliferation and migration of rat 
aortic smooth muscle cells when supplemented in cell culture media. 
3.2. MATERIALS AND METHODS 
3.2.a Cell Culture 
Primary rat aortic smooth muscle cells (RASMCs) purchased from Cell 
Applications Inc, were seeded at passages 8-10 on well plates for all experiments. Cells 
were grown in DMEM with 10% fetal bovine serum and 1% penicillin-streptomycin. 
TNFα (rat recombinant, Peprotech Cat# 400-14) and PGG (kind gift from OmniChem, 
Belgium) were supplemented in cell culture media as described below. 
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In preliminary experiments (n=2 per group), cells were treated with 0 ng/ml, 10 
ng/ml, 50 ng/ml, and 100 ng/ml of TNFα to determine the effect on MMP-2 and 
cathepsin L activity. A p value of equal to or less 0.05 was considered statistically 
significant; however more samples are necessary to obtain meaningful results. 
From the results of the preliminary experiments, a concentration of 50 ng/ml of 
TNFα was determined to be optimal for our experiments (results described in section 
3.4a). Further experiments were conducted as described in the following paragraphs. 
3.2.b Experimental groups 
TNFα and PGG were added simultaneously at day 0 and samples collected at days 
1, 3 and 6. Delayed group (D6) consisted of cells supplemented with TNFα at day 0, 
PGG added at day 3, and samples were collected at day 6. 
3.2.c Live/dead assay 
RASMCs were grown with TNFα, PGG, or both added together. Cells grown in 
absence of either TNFα or PGG were considered as a control group. At the end of 6 days, 
cell viability was determined using a LIVE/DEAD Cell Viability assay (Molecular 
Probes L3224). Cells fluorescing green are considered alive while cells fluorescing red 
are considered dead. 
3.2.d Proliferation assay 
Proliferation of cells was estimated using the MTT (3-(4,5-Dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide) assay. Equal number of cells were seeded and 
treated with TNFα, PGG, both added together. Cells grown in the control group were not 
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treated with either TNFα or PGG. Cell proliferation at day 0 (before any treatment) was 
also assessed to confirm that equal numbers of cells were seeded. Briefly, 5 mg of MTT 
(Sigma M2128) was dissolved in 10 ml of serum-free media and added to cells. After 4 
hours, media was carefully aspirated and the insoluble formazan dye was collected with 
acidified isopropanol. Absorbance was read at 560 nm and normalized to control (no 
treatment) readings. 
3.2.e Real-time PCR 
RNA was isolated from cells using GE Illustra mini RNA isolation kit and 
quantified using the Agilent 2100 bioanalyzer. Equal amounts of RNA were reverse 
transcribed with the Applied Biosystems High Capacity reverse transcription kit. Real-
time PCR was conducted using Qiagen SYBR green master mix on the Rotorgene PCR 
machine. Delta-delta Ct method was used to calculate relative gene expression with 18S 
rRNA as the housekeeping gene.
111
 
3.2.f Gelatin zymography 
Protein samples were normalized to total protein quantified using bicinchoninic 
acid assay (Pierce). Equal quantities of protein were loaded with non-denaturing buffer in 
wells of pre-cast gelatin zymogram gel (Biorad 161-1131) and run at 85V for 120 
minutes. The gels were then washed in 2.5% Triton X-100 for 30 minutes and incubated 
overnight in activation buffer to detect MMP-2, -9 (50mmol/L Tris-base, 5mmol/L 
calcium chloride, 200mmol/L sodium chloride, 0.02% brij pH 7.5). The gels were then 
stained with commassie blue, destained and imaged. Densitometric analysis was 
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performed using ImageJ software.
112
 Average densities of experimental groups were 
normalized to the control (no treatment) group and plotted as percentage of control. 
3.2.g Western blot 
Cells were grown as described earlier with some modifications to detect 
cathepsins in conditioned media. Twenty four hours before time of collection, media was 
replaced with serum-free media containing the corresponding supplements. Serum-free 
conditioned media was collected at days 2, 3 and 6 and concentrated 20-30X using 
Amicon 10 kDa molecular cut-off filters. Total protein was quantified with bicinchoninic 
acid assay (Pierce). Equal amounts of protein were boiled with denaturing buffer and 
loaded in pre-cast gels (Biorad 161-1102). Gels were run at 85V for 120 minutes and 
transferred to PVDF membrane (Millipore) at 50V for 120 minutes. The blots were 
blocked in 5% non-fat dry milk (LabScientific) overnight at 4 
o
C, incubated in primary 
antibodies against cathepsin S (SCBT sc-30057, rabbit anti-rat), cathepsin K (Biovision 
3588-100, rabbit anti-rat) and cathepsin L (Abcam ab6314, mouse anti-rat). This was 
followed by incubation with secondary antibody (anti-mouse/rabbit) and detection 
(Roche BM Chemiluminescence kit, anti-mouse/rabbit). Bands were imaged with Alpha 
Innotech chemiluminescence detector. 
3.2.h Migration assay 
In vitro scratch test was conducted to study cell migration in response to injury. 
Previously published protocol for the scratch assay was followed.
113
 Briefly, cells were 
seeded onto 6 well plates and grown until confluence. A ‘scratch’ was made with a sterile 
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pipette tip to simulate a wound. TNFα, PGG, or both together were added (0 hr). A 
control group cells were ‘scratched’ without any treatment. Images of the scratch area 
were taken at 0, 24 and 48 hours.  
3.2.i Data analysis 
Results are expressed as mean ± SEM with triplicates for all experimental groups. 
Statistical analysis of data was calculated using student’s t-test and probability value (p) 
was calculated. A p-value equal to or less than 0.05 was considered statistically 
significant. 
3.3. RESULTS 
3.3.a Results of preliminary experiments 
The activities of MMP-2, MMP-9 and cathepsin L were determined by gelatin 
zymography. RASMCs treated with various concentrations of TNFα and the cathepsin L 
activity levels from 3 day cell lysates are shown by zymography in Figure 3.1. TNFα 
increased the activity of cathepsin L at all the concentrations used as shown by 
densitometric analysis in a dose dependent manner (Figure 3.2).  
MMP-2 activity in cells treated with various concentrations of TNFα was detected 
by zymography as shown in Figure 3.3. Densitometric analysis of MMP-2 zymogram is 
shown in Figure 3.4. Since the concentration of 50 ng/ml caused a noticeable increase in 
cathepsin L activity (1.5 fold) of 3 day cell lysates and 1.4 fold increase in MMP-2 
activity, TNFα was used at this concentration for subsequent experiments. 
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Figure 3.1: Gelatin zymography for cathepsin L activity in day 3 lysates 
 
 
Figure 3.2: Densitometric analysis of cathepsin L zymogram in day 3 lysates. * indicates 
statistically significant with p<0.05 and n=2. 
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Figure 3.3: Gelatin zymography for MMP-2 in day 3 conditioned media 
  
Figure 3.4: Densitometric analysis of MMP-2 zymogram of day 3 conditioned media. * 
indicates statistically significant with p<0.05 and n=2. 
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3.3.b PGG did not cause cytotoxicity in rat aortic smooth muscle cells 
Live/dead assay was conducted to determine any cytotoxic effects of 50 ng/ml 
TNFα, 10 µmol/L PGG or their combination on RASMCs. The results of live/dead assay 
(Figure 3.5) showed similar numbers of dead cells in all groups. This demonstrates that 
50 ng/ml TNFα, 10 µmol/L PGG, or their combined treatment have no significant 
cytotoxic effects the concentrations used in our experiments. Previously, PGG has been 
shown to induce minimal cytotoxic effects at concentrations of 0.03% - 0.3%.
109
 As seen 
in Figure 3.5, images of the cells show minimal number of dead cells as denoted by red 
fluorescence. These images also showed that RASMCs treated with 50 ng/ml TNFα 
became more cuboidal in morphology suggesting a deviation from the usual spindle-
shape of aortic smooth muscle cells. When PGG was combined with TNFα, more cells 
had spindle shaped morphology at the end of 6 days suggesting that PGG maintained 
smooth muscle cells in their native state. In order to determine if proliferation of these 
cells were affected by the treatments, MTT assay was performed as described in section 
3.3.g. 
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Figure 3.5: Live/dead assay of RASMCs treated with TNFα (A), TNFα+PGG (B), PGG (C) 
or no treatments (D) for 6 days. Green fluorescence shows live cells while red fluorescence 
denotes dead cells. 
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3.3.c PGG significantly decreased transcription of proteolytic enzymes 
The effect of TNFα and PGG on the gene expressions of proteolytic enzymes was 
examined. Real-time PCR results demonstrated that PGG significantly affected the gene 
expression levels of cathepsins at day 3 as shown in Figures 3.6. Cathepsins K (CTSK) 
gene expression was increased more than 7-fold by TNFα. When PGG was added along 
with TNFα, gene expression of cathepsin K in RASMCs was decreased to 3-fold. 
Cathepsin S (CTSS) gene expression was dramatically increased by TNFα (160-fold) 
compared to the control cells. PGG down regulated the mRNA levels of cathepsin S by 
more than 60%. Cathepsin L (CTSL) and cystatin C (Cys C) gene levels were not 
significantly affected due to the treatments.  
Expression levels of cathepsins at day 6 are shown in Figure 3.7. At day 6, TNFα 
increased the gene expression of cathepsin K.  PGG, when added together with TNFα, 
decreased the expression of cathepsin K but not significantly. Cathepsin S gene 
expression due to TNFα treatment showed 80-fold increase which is 50% of the 
expression at day 3. However, adding PGG along with TNFα did not decrease the 
expression of cathepsin S gene at day 6. Cathepsin L and cystatin C gene expression did 
not differ considerably due to treatments.  
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Figure 3.6: Real-time PCR of proteolytic enzymes in day 3 RASMCs. * indicates 
significantly different from the control group and + indicates significantly different from 
the TNFα group (p<0.05). 
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Figure 3.7: Real time PCR of proteolytic enzymes in day 6 RASMCs. * indicates 
significantly different from the control group and + indicates significantly different from 
the TNFα group (p<0.05). 
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3.3.d PGG significantly inhibits MMP-2 activity in conditioned media 
Zymography was conducted on conditioned media samples in order to assess the 
activity of MMP-2 and MMP-9 enzymes that were released into the extracellular milieu. 
Gelatin zymography results showed that MMP-2 activity was significantly increased with 
TNFα treatment. Cells grown with TNFα showed increased activity of both pro-MMP-2 
(72 kDa) and active MMP-2 (68 kDa). At days 1 and 3, PGG significantly reduced the 
activity of pro MMP-2 and at days 3 and 6, PGG inhibited active MMP-2 significantly. In 
contrast, the addition of PGG to cultures (without TNFα) decreased the activity of pro-
MMP-2. 
When PGG was added 3 days post addition of TNFα, MMP-2 activity was not 
significantly inhibited by PGG. PGG may not thus be effective at reversing the increase 
in activity of MMP-2 due to treatment with TNFα. 
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Figure 3.8: MMP-2 zymogram and densitometric analysis of day 1 conditioned media. * 
indicates significantly different from the control group and + indicates significantly 
different from the TNFα group (p<0.05).  
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Figure 3.9: MMP-2 zymogram and densitometric analysis of day 3 conditioned media. * 
indicates significantly different from the control group and + indicates significantly 
different from the TNFα group (p<0.05).  
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Figure 3.10: MMP-2 zymogram and densitometric analysis of day 6 conditioned media. * 
indicates significantly different from the control group and + indicates significantly 
different from the TNFα group (p<0.05). 
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Figure 3.11: MMP-2 zymogram and densitometric analysis of D6 conditioned media. * 
indicates significantly different from the control and + indicates significantly different from 
the TNFα group (p<0.05). 
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3.3.e TNFα and PGG regulate MMP-9 activity 
Gelatin zymography was conducted to estimate MMP-9 activity in conditioned 
media of RAMSCs. Pro-MMP-9 activity in the TNFα group was decreased or not 
significantly different from the control group at all time points (Figures 3.12, 3.13, 3.14, 
and 3.15). Active MMP-9 was regulated differently than pro-MMP-9. All experimental 
groups showed active MMP-9 levels not very different from control group (less than 5% 
difference) at day 1 and day 3. At day 6, active MMP-9 levels were significantly higher 
in all experimental groups compared to the control group. At day 6, group with PGG and 
TNFα showed significantly higher pro-MMP-9 activity than both control group and 
TNFα groups. MMP-9 activity was regulated differently than MMP-2 in our experiments. 
The increase in MMP-9 activities in groups treated with PGG could be a compensatory 
mechanism for the decrease in MMP-2 activities. However, the differential regulation of 
MMP-9 could have other implications both in vitro and in vivo. 
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Figure 3.12 MMP-9 zymogram and densitometric analysis of day 1 conditioned media. * 
indicates significantly different from the control group (p<0.05). 
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Figure 3.13 MMP-9 zymogram and densitometric analysis of day 3 conditioned media. * 
indicates significantly different from the control group and + indicates significantly 
different from the TNFα group (p<0.05). 
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Figure 3.14 MMP-9 zymogram and densitometric analysis of day 6 conditioned media. * 
indicates significantly different from the control group and + indicates significantly 
different from the TNFα group (p<0.05). 
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Figure 3.15: MMP-9 zymogram and densitometric analysis of D6 conditioned media. * 
indicates significantly different from the control group and + indicates significantly 
different from the TNFα group (p<0.05). 
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3.3.f PGG causes a decrease in extracellular levels of cathepsins K, L and S  
Western blot analysis of potent proteolytic cathepsins K, L and S was conducted 
to determine amounts of cathepsins K, L and S. Cathepsin K levels in conditioned media 
at different time points are shown in Figure 3.16. TNFα increased the level of 
extracellular cathepsin K at all time points. At day 2 and day 6, PGG reduced the levels 
of cathepsin K when added together with TNFα. At day 3, cathepsin K inhibition due to 
PGG was not noticeable. PGG treatment alone showed reduced the amount of cathepsin 
K at day 1 and day 6 compared to the control group. PGG, when added 3 days past TNFα 
treatment did not show any noticeable difference in cathepsin K level. 
Cathepsin L levels in the conditioned media detected by Western blotting is 
shown in Figure 3.17. Western blot of conditioned media in the PGG (without TNFα) 
group showed no detectable cathepsin L levels at all time points, including the D6 group. 
Control group conditioned media also showed barely detectable levels of cathepsin L at 
day 3 and no detectable cathepsin L at day 2, day 6 and D6. The addition of TNFα 
increased amount of cathepsin L while the combination of TNFα and PGG treatments 
showed decreased levels of cathepsin L. PGG was able to reverse the increase in 
cathepsin L induced by TNFα in the D6 experimental group. 
Cathepsin S was detected using Western blotting at specified time points as 
shown in Figure 3.18. PGG dramatically inhibited the amount of cathepsin S at all time 
points, even when added after 3 days post treatment with TNFα. PGG treatment alone 
showed very low levels of cathepsin S at all time points.
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Figure 3.16: Western blotting for cathepsin K in conditioned media. Lanes 1-2: 50 ng/ml 
TNFα, 3-4: 50 ng/ml TNFα + 10 µmol/L PGG, 5-6:10 µmol/L PGG, 7-8: Control (no 
treatment). 
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Figure 3.17: Western blotting for cathepsin L in conditioned media. Lanes 1-2: 50 ng/ml 
TNFα, 3-4: 50 ng/ml TNFα + 10 µmol/L PGG, 5-6: 10 µmol/L PGG, 7-8: Control (no 
treatment). 
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Figure 3.18: Western blotting for cathepsin S in conditioned media. Lanes 1-2: 50 ng/ml 
TNFα, 3-4: 50 ng/ml TNFα + 10 µmol/L PGG, 5-6: 10 µmol/L PGG, 7-8: Control (no 
treatment). 
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3.3.g Rat aortic smooth muscle cell proliferation is inhibited by PGG 
MTT assay was conducted to estimate the effect of PGG treatments on cell 
proliferation at different time points. Average absorbances of the experimental groups 
were plotted as percentages of control were (Figure 3.19). TNFα caused significant 
increase in proliferation of RASMCs at day 6. PGG reduced this increase in proliferation 
significantly at day 6. PGG treatment also decreased proliferation significantly at day 6. 
As demonstrated by the live/dead assay in Figure 3.5, PGG does not exert cytotoxic 
effects. Thus, PGG inhibits proliferation by preventing cell division and not by causing 
cell death.
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Figure 3.19: Proliferation of RASMCs as measured by the MTT assay. * indicates 
significantly higher than the control group and + significantly lower than the TNFα group 
(p<0.05). 
 58 
 
3.3.h PGG reduces cell migration induced by injury 
The in vitro scratch assay was conducted to assess cell migration. This assay is 
helpful in determining the speed with which the cells will migrate to fill an artificially 
induced ‘wound’. Images from the scratch assay are shown in Figure 3.20. Cells treated 
with TNFα proliferate and migrate towards the gap more rapidly than the control group. 
PGG when added simultaneously with TNFα decreased the migration and appeared to 
have a more flattened morphology. PGG treatment alone shows very limited migration 
and proliferation compared to control. Outline of the scratch is still detectable in the PGG 
group after 48 hours of the scratch.  
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Figure 3.20: RASMC migration assessed using the scratch test. Dotted lines indicate the 
approximate boundaries of scratch. 
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3.4. DISCUSSION 
In this study, we supplemented media of RASMCs with TNFα to simulate a 
condition that mimics inflammatory conditions associated with atherosclerosis, 
aneurysms and restenosis in vivo. Although this is not a complete representation of in 
vivo conditions, TNFα has been shown to induce increased expression and activities of 
several proteolytic enzymes in vitro. We studied the activities of MMP-2 and MMP-9 
using gelatin zymography. We also assessed the amounts of cathepsins K, L and S in the 
conditioned media. Cell migration and proliferation were also assessed using scratch test 
and MTT assay respectively.  
Cathepsins and matrix metalloproteases are important mediators in various 
pathological conditions.
114
 Atherosclerosis and restenosis often involve excess 
proliferation of vascular smooth muscle cells (VSMCs) in response to injury.
115,116
 
Atherosclerosis, initiated by deposition of fatty acids, involves release of inflammatory 
factors such as tumor necrosis factor and interleukins.
117-120
 These cytokines are linked to 
increased proliferation of various types of cells including VSMCs. VSMCs respond to 
injury by increased proliferation and deposition of extracellular matrix, mainly collagen 
in the surrounding area. In cases of minor injury, the process continues towards healing 
the injury and repairing any damage. However, atherosclerosis and restenosis are chronic 
conditions leading to a vicious cycle that sustain inflammatory conditions. VSMCs in 
chronic inflammatory conditions release extracellular matrix proteases that degrade 
collagen and elastin.
121-123
 The release of extracellular matrix fragments interact with 
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cellular receptors and induce further release of inflammatory cytokines from newly 
formed VSMCs as well as macrophages in the area.
124,124-127
 This vicious cycle persists 
until the lumen is occluded and surgical or pharmaceutical measures are taken. A similar 
process takes place in case of aneurysms. Initial injury is brought on by atherosclerosis, 
genetic predisposition or lifestyle factors such as smoking. VSMCs and macrophages 
secrete elastases and collagenases causing the local arterial wall to weaken. The VSMCs 
then produce excess collagen to compensate for reduced mechanical strength associated 
with degraded elastin. Freshly synthesized collagen is more easily degraded by the 
released proteases resulting in a vicious cycle of collagen deposition and degradation. 
Pro-inflammatory cytokines such as TNFα have been strongly associated with 
aneurysms.
128-131
 Using zymography, a technique that can demonstrate proteolytic 
activity, we confirmed that TNFα induces increased activities of extracellular MMP-2 
and intracellular cathepsin L. Western blot analysis shows that cathepsin S, K and L 
release into the extracellular milieu is also augmented by TNFα. This simulates 
pathological conditions associated with atherosclerosis, restenosis and aortic aneurysms 
that lead to degradation of elastic fibers and collagen within the arterial wall. Inhibition 
of MMPs and cathepsins has shown to be beneficial in multiple diseases including 
vascular pathologies. Other dietary polyphenols have shown that some dietary 
polyphenols can have inhibitory activity against some proteolytic enzymes.
106, 132
 In our 
studies, we have looked at the effect of PGG on cathepsins, which has not been 
established previously. We showed that PGG can be used as an inhibitor of MMP-2, 
cathepsins K, L & S and it can potentially protect elastin in the arterial walls from 
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degradation. Cathepsins K, L and S have been shown to play an important role in 
vascular pathology including atherosclerosis, plaque stability, and arterial calcification. 
133-136
 TNFα is known to induce the expression of proteolytic enzymes by various types 
of cells.
137-140,116,137
 PGG inhibits the amount of cathepsins K, L & S released by VSMCs 
into the extracellular space as shown by Western blot analysis. Increased gene expression 
of cathepsins K & S induced by TNFα was also markedly decreased by PGG as shown by 
PCR analysis of 3 day samples. Initially, we had hypothesized that PGG cross-links 
elastin and thus increases its resistance to proteolytic enzymes. While this has been 
shown both in vitro and in vivo, PGG was used in high concentrations to effectively 
cross-link elastin (0.06%) and collagen (0.3%).
109,110,141
 In our studies, we have used 
relatively very low concentrations (10 µmol/L) of PGG. We believe that at these low 
concentrations, PGG has intracellular effects that were not studied or observed in 
previous studies. PGG inhibited the activity of pro-MMP-2 in the earlier time points and 
reduced the activity of active MMP-2 in the later time points. MMP-9 activity of the 
RASMCs was upregulated by PGG. Studies on various human cells have shown that 
TNFα increases MMP-9 activity.142-144 However, the zymography results from our 
experiments suggest that rat derived cells may respond differently than human cells in 
their MMP-9 activity in response to TNFα. It is not clear if PGG directly affects the 
activity of MMP-9 or the increase in MMP-9 activity is due to RASMCs compensating 
for reduced MMP-2 activity. 
Atherosclerosis and restenosis also involve the migration of VSMCs into the 
lumen, where the endothelial layer has been compromised due to fatty acid deposition or 
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surgical intervention (balloon angioplasty).
105,145
 Increased proteolytic activity can reduce 
extracellular matrix composition thus making it easy for VSMCs to migrate towards the 
lumen. Some polyphenols have been shown to inhibit the proliferation of cancer cells and 
VSMCs through interference in cell cycle signaling.
146-149
 Our studies have shown that 
PGG significantly inhibits proliferation of rat aortic smooth muscle cells without being 
cytotoxic. We hypothesize that PGG affects the cell cycle signaling and maintains the 
cells in a ‘differentiated’ state by preventing DNA synthesis and mitosis. More research 
needs to be done to confirm this hypothesis. 
As discussed above, migration and proliferation occur frequently in vascular 
diseases. The scratch test results showed that PGG inhibits the migration of smooth 
muscle cells in the in vitro model of vascular injury. Migration is closely linked to the 
release of proteolytic enzymes since cells need to degrade extracellular matrix in order to 
migrate and inhibition of proteolytic enzymes could be a potential approach to controlling 
migration of cells. In our study, PGG inhibited proteolytic enzymes and migration 
effectively. We conclude that PGG not only stabilize extracellular matrix but can have 
intracellular effects through control of gene and protein expressions of proteolytic 
enzymes. More studies are needed to understand the potential therapeutic effects and any 
unexpected side effects of PGG. 
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CHAPTER 4  
CHARACTERIZATION OF INCREASED TROPOELASTIN PRODUCTION 
AND INCREASED DEPOSITION OF INSOLUBLE ELASTIN BY PRIMARY 
RAT AORTIC SMOOTH MUSCLE CELLS TREATED WITH 
PENTAGALLOYLGLUCOSE 
4.1. INTRODUCTION 
Elastic fibers are an important part of the extracellular matrix in various tissues. 
They provide important mechanical properties like elasticity and resilience. Tropoelastin 
is the soluble elastin that is released by cells. It is assembled within microfibrillar 
glycoproteins present the matrix and then crosslinked by lysyl oxidase to form insoluble 
elastic fibers. Mature elastic fibers consist of elastin cores and microfibrils at the 
periphery.
80
 Elastin is a major constituent of several tissues including aorta (57%), elastic 
ligaments (50%), lung (7%) and skin (5%).
81
 Importance of elastin has been elucidated 
by knockout mice. Heterozygous mice (ELN+/-) had decreased arterial compliance with 
hypertension but had a normal life expectancy. The physical properties of the blood 
vessels can be explained by arterial remodeling due to reduced amount of elastin. These 
mice also displayed altered aging processes in the aorta which suggests the importance of 
elastin arrangement during early stages in the formation of the vessel.
82
 Complete lack of 
the elastin gene ELN-/- results in early mortality of mice due to extensive, uncontrolled 
proliferation of smooth muscle cells and consequent vessel obstruction.
83
 The amino acid 
sequence of tropoelastin has hydrophilic and hydrophobic domains alternating with each 
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other. The hydrophobic domains are rich in glycine, valine and proline, occurring in 
repeating motifs. Hydrophilic regions are rich in lysine and alanine which are involved in 
crosslinking of elastin.  
Human tropoelastin is encoded by a single gene with multiple isoforms. Eleven 
forms of human tropoelastin splice forms have been characterized. The tropoelastin 
mRNA encodes a 72kDa protein and with the removal of signal peptide, resulting in a 
mature protein of 60kDa.
84
 The C-terminus is one of the most important and well-
conserved regions in tropoelastin. It contains the only two cysteine residues which form 
the disulfide bond. The protein terminates with a positively charged sequence RKRK. 
Any major disruption in the C-terminus like the disruption of the disulphide bond can 
drastically reduce the ability of tropoelastin to assemble and form elastic fibers.
85
 The 
tertiary structure of the cross linked elastin has not been fully determined but significant 
research has characterized the secondary structure.
86
 Tropoelastin secondary structure 
also includes poly-proline II, compact beta turns and disordered structure, which 
contribute to its highly flexible nature.
87
 In vascular tissue, elastin synthesis occurs as 
shown in Figure 4.1. The cells secrete tropoelastin which is believed to be chaperoned by 
the 67kDa protein (elastin-laminin receptor or ELR) to the cell surface.
88
 Tropoelastin, 
once released into the extracellular space, self assembles into globules of several microns. 
These globules remain attached to the cells surface in the early stages. The globules are 
cross-linked by copper dependent enzyme called lysyl oxidase and aligned along the 
microfibril scaffolds.
89
 Once mature, cross-linked elastin is formed and deposited in the 
extracellular space, and tropoelastin production is reduced. Turnover of mature elastin is 
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very low, with most of elastin formation occurring in late fetal and early neonatal periods 
in mammals. By adulthood, elastin production is very low or non-existent.
90
 Tropoelastin 
production can resume in case of injury and is affected by various factors like TNFα, IL-
1, insulin-like growth factor-1 and especially transforming growth factor-beta (TGFβ).91 
 
Figure 4.1: Elastin fiber synthesis from tropoelastin 
89
 
The human elastin gene has a functional promoter that exhibits upstream and 
downstream regulatory elements. Cyclic adenosine monophosphate (cAMP), 
glucocorticoid and insulin-like growth factor (IGF) responsive elements are present in 
this region indicating that tropoelastin production is influenced by growth factors.
91,92
 
Elastin mRNA production can be influenced by insulin-like growth factor and post-
transcriptionally by TGFβ, which stabilizes the transcripts considerably.93,94 
The complex process of elastogenesis begins with the formation of the 
tropoelastin molecule. A 67 kDa ELR (also referred to as the chaperone), a spliced 
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variant of the beta-galactosidase acts as a chaperone for tropoelastin as shown in Figure 
4.2. The 67kDa ELR binds to the tropoelastin and this prevents premature aggregation of 
elastin in the intracellular space.
95
 The complex is transported to the extracellular space 
where the chaperone molecule releases the tropoelastin molecule. The chaperone has a 
higher affinity for galactosugars than for tropoelastin resulting in release of tropoelastin. 
The 67 kDa ELR is recyclable and is internalized again after tropoelastin release.
96
 The 
significance of the C-terminal domain of tropoelastin is evident as its interaction with the 
N-terminal of the microfibrillar associated glycoprotein is crucial for correct 
elastogenesis.
97
 After the action of lysyl oxidase and coacervation of tropoelastin 
microspheres, alignment occurs on the microfibrils. Formation of cross links causes the 
elastin to become insoluble.
98
 The 67kDa ELR that acts as the chaperone for tropoelastin 
is also referred to as the elastin binding protein (EBP). Multiple studies have shown the 
role of ELR in various cell responses. ELR is involved also in responding to products of 
elastin degradation. 
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Figure 4.2: Elastin synthesis using the elastin binding protein (chaperone) 
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Degradation of elastin is an important aspect of diseases such as aneurysms, 
atherosclerosis and vascular calcification. In earlier studies, pentagalloylglucose (PGG) 
has been used to preserve the morphology of elastin and prevent its degradation in vivo. 
We wanted to investigate the effects on the production of elastin in rat aortic smooth 
muscle cells. Our aim was to determine to what extent PGG behaved as a fixative in vitro 
for elastin, by preventing elastin degradation due to proteolytic enzymes. This study also 
observed that PGG had other effects on smooth muscle cells. 
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4.2. MATERIALS AND METHODS 
4.2.a Cell culture 
Primary rat aortic smooth muscle cells (RASMCs) were seeded on 12-well plates and 
grown in DMEM containing 20% fetal bovine serum and 1% penicillin-streptomycin. 
Media was supplemented with different concentrations of PGG, a kind gift from 
Omnichem (Belgium).  
4.2.b Fastin colorimetric assay for elastin 
Cell lysates were collected at set time points and tropoelastin was quantified using a 
colorimetric method (Fastin kit, Biocolor). Insoluble elastin was extracted with hot oxalic 
acid while soluble elastin (tropoelastin) was obtained from supernatant obtained by 
centrifugation of cell lysates.  
4.2.c Western blot for tropoelastin 
Cell lysates were collected with mammalian extraction buffer (Solulyze-M, Gelantis) and 
total protein quantified with bicinchoninic acid assay (Pierce). Equal amounts of protein 
were boiled in denaturing buffer and loaded in pre-cast gels (Biorad 161-1102). Gels 
were run at 85V for 120 minutes and transferred to PVDF membrane (Millipore) at 50V 
for 120 minutes. The blots were blocked in 5% non-fat dry milk (LabScientific) overnight 
at 4 C, and then incubated with the primary antibody (RDI# TP592 rabbit anti-elastin) 
against tropoelastin. This was followed by incubation with secondary antibody and 
detection (Roche BM Chemiluminescence kit anti-mouse/rabbit). Bands were imaged 
with Alpha Innotech chemiluminescence detector. 
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4.2.d Gelatin zymography for cathepsin L 
Protein samples were normalized to total protein quantified using bicinchoninic 
acid assay (Pierce). Equal quantities of protein were loaded with non-denaturing buffer in 
wells of pre-cast gelatin zymogram gel (Biorad 161-1131) and run at 85V for 120 
minutes. The gels were then washed in 2.5% Triton X-100 for 30 minutes and incubated 
overnight in activation buffer to detect cathepsin L (100mmol/L sodium acetate pH 4.8, 
20mmol/L L-cysteine). The gels were then stained with commassie blue, destained and 
imaged. Image analysis was performed using ImageJ. 
4.2.e Data analysis 
Results are expressed as mean ± SEM for triplicates for all experimental groups. 
Statistical analysis of data was calculated using student’s t-test and probability value (p) 
was calculated and p<0.05 was considered statistically significant. 
4.3. RESULTS 
We conducted experiments with RASMCs from different sources in order to 
determine if PGG affects elastin production due to source of RASMCs. Similar studies 
were conducted to compare elastin production by RASMCs derived from adult or 
neonatal rats, freshly isolated or previously frozen (in 10% dimethyl sulfoxide in liquid 
nitrogen). 
In our pilot studies, we used 3 concentrations of PGG - 1µmol/L, 10µmol/L and 
25µmol/L supplemented in media of freshly isolated primary adult RASMCs. Fastin 
assay was conducted on cell lysates to assess quantity of soluble tropoelastin and 
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insoluble elastin, and the values were plotted as percentages relative to the untreated 
control group (shown in Figure 4.3). At the end of 4 weeks, 25µmol/L PGG increased the 
amount of tropoelastin significantly compared to control as shown in Figure 4.4. 
Insoluble elastin was significantly higher in the cells treated with 10µmol/L PGG. 
Insoluble elastin in the cells treated with 25µmol/L PGG was too low to be detected using 
the Fastin kit and hence were not included in the figure. Furthermore, most cells died by 
the end of 4 weeks when treated with 25µmol/L PGG. 
Next, we used a lower concentration of PGG so we can compare the effects of 3 
PGG non-cytotoxic concentrations. We conducted a 4 week study with 100 nmol/L, 1 
µmol/L, 10 µmol/L PGG, and without PGG (control). These concentrations were used on 
freshly isolated primary adult RASMCs, previously frozen adult primary RASMCs, and 
previously frozen neonatal primary RASMCs.  
Freshly isolated primary adult RASMCs showed increased insoluble elastin 
deposition at the end of 4 weeks as shown in Figure 4.5. Previously frozen primary adult 
RASMCs and neonatal RASMCs did not show an increase in elastin production due to 
PGG treatment as shown in Figure 4.6 and Figure 4.7 respectively. Almost all the 
neonatal RASMCs died by the end of 4 weeks when treated with 10 µmol/L PGG and 
hence elastin was not detectable in that group. Neonatal RASMCs are potentially more 
sensitive than adult RASMCs to similar concentrations of PGG. 
For further studies, only one concentration of PGG (10µmol/L) was used since 
this concentration provided increased production of insoluble elastin relative to control as 
shown in Figures 4.4, and 4.5. Freshly isolated primary adult RASMCs were treated with 
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either 10 µmol/L PGG or no treatment (control). Fastin colorimetric assay was used to 
quantify tropoelastin and insoluble elastin, both of which showed significant increase 
compared to control as shown in Figure 4.8. Western blotting confirmed the Fastin assay 
results as shown in Figure 4.9. Gelatin zymography to detect cathepsin L showed a 
dramatic decrease in the activity of the enzyme in the cells treated with PGG as seen in 
Figure 4.10. 
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Figure 4.3: Tropoelastin in 4 week RASMC lysates. * indicates significantly higher than the 
control group 
  
Figure 4.4: Insoluble elastin in 4 week RASMCs. * indicates significantly higher than the 
control group 
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Figure 4.5: Insoluble elastin in 4 week freshly isolated primary adult RASMCs. * indicates 
significantly higher than the control group 
 
Figure 4.6: Insoluble elastin in 4 week primary adult RASMCs that were previously frozen 
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Figure 4.7: Insoluble elastin in 4 week neonatal primary RASMCs that were previously 
stored in liquid nitrogen. 
 
Figure 4.8: Elastin quantification in 4 week freshly isolated primary adult RASMCs. * 
indicates significantly higher than the control group (p<0.05) 
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Figure 4.9: Western blotting for elastin from 4 week freshly isolated primary adult RASMC 
lysates 
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Figure 4.10: Gelatin zymography for cathepsin L in 4 week cell lysates 
4.4. DISCUSSION 
PGG increases the amount of tropoelastin and insoluble elastin produced by 
primary rat aortic smooth muscle cells that have not been previously frozen. We found 
that the optimal concentration of PGG for this purpose is 10µmol/L. 
However, experiments with frozen RASMCs cultured with PGG showed no 
significant increase in elastin production due to PGG. These results suggests that freezing 
these cells caused some critical change in the of elastin production process and, this 
change altered the response of these cells to PGG.  
PGG could potentially be used to increase the amount of cross-linked elastin in 
arterial tissue. Delivery of PGG to aneurysmal arteries can help to increase the production 
of elastin by the rat aortic smooth muscle cells. When used at higher concentrations, PGG 
was a fixative for native elastin in aorta and prevented elastases from degrading 
elastin.
109,110
 However, the concentrations of PGG we have used in these in vitro studies 
are much lower and cause changes in proteolytic activity of the rat aortic smooth muscle 
cells. The delivery mode and optimal concentration of PGG to be delivered in vivo in to 
have increased elastogenesis have to be determined. Once these parameters have been 
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optimized, PGG could be a potential therapeutic agent that reverses the degradation of 
elastin and aids in deposition of newly formed insoluble elastin. 
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CHAPTER 5  
CHARACTERIZATION OF PENTAGALLOYLGLUCOSE INDUCED ANTI-
OSTEOGENIC DIFFERENTIATION OF TUMOR NECROSIS FACTOR-ALPHA 
ACTIVATED RASMCS  
5.1. INTRODUCTION 
Ectopic mineralization of arteries is associated with other diseases such as 
atherosclerosis, hypercholesterolemia, diabetes, and chronic kidney disease. Vascular 
calcification is an active, cell-mediated process that involves dedifferentiation of vascular 
smooth muscle cells into osteogenic cells and the deposition of calcium phosphate in 
arterial walls.
150,151
 Healthy arterial smooth muscle cells are contractile, non-proliferative 
and exhibit markers such as smooth muscle actin and heavy chain myosin. Inflammatory 
conditions resulting from an initial injury, such as deposition of fatty acids or 
hypertension, causes the migration of monocytes from the bloodstream into the 
subendothelial layer. The monocytes differentiate into macrophages and release pro-
inflammatory cytokines and proteolytic enzymes. The cytokines and proteases in the 
subendothelial and medial regions create a local inflammatory zone where the smooth 
muscle cells are induced to proliferate, migrate and dedifferentiate.
10,152,153
 Migration of 
smooth muscle cells into the luminal area and their excess proliferation can cause 
stenosis (narrowing) of the arterial lumen. Balloon angioplasty can surgically increase the 
diameter of a stenotic artery but often this leads to a relapse with increased migration and 
proliferation of the smooth muscle cells called ‘restenosis’.104,154,155 In case of vascular 
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calcification, markers of osteogenic differentiation such as increased alkaline phosphatase 
activity, increased core binding factor alpha-1 (CBFA-1), increased muscle segment 
homeobox -2 (MSX-2), and deposited of calcium phosphate can be observed in vascular 
smooth muscle cells.
156-158
 Extensive meta-analyses have shown that osteoporosis and 
vascular calcification often occur simultaneously. Patients with osteoporosis also show 
increased incidences of vascular medial calcification. Osteoporosis is characterized by an 
imbalance between bone deposition (by osteoblasts) and bone resorption (by osteoclasts) 
leading to excess loss of mineralization. Vascular calcification, on the other hand is the 
ectopic mineralization of arterial tissue with increased osteoblastic activity.
159,160,161
 Thus, 
any therapeutic agent for either diseases should not adversely affect the other.  
Vascular smooth muscle cell (VMSC) calcification in vitro has been studied in the 
past by using various methods. Mimicking hyperphosphatemic and/or hypercalcemic 
conditions are common and convenient methods to simulate in vitro.
162
 Adding beta 
glycerophosphate to the media is the most common method of inducing 
hyperphosphatemia cell culture.
163,164
 Primary human vascular smooth muscle cells 
grown hypercalcemic and hyperphosphatemic media showed higher calcification.
165
 
However, this occurred only in the presence of cells and hence must involve cellular 
processes. In addition, osteogenic markers CBFA-1, alkaline phosphatase mRNA levels 
were also increased.
34
 
Other methods of inducing osteogenic differentiation of vascular smooth muscle 
cells in vitro include addition of elastin peptides and addition of oxidative stress factors 
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such as hydrogen peroxide and oxidized-low density lipoproteins.
124,166
Addition of 
osteogenic proteins such as BMP-2 also induce osteoblast-like features in aortic smooth 
muscle cells.
167
 In order to create an in vitro model that mimicked an inflammatory 
condition, we used TNFα. Earlier studies have shown that supplementing TNFα in the 
media of vascular smooth muscle cells causes an increase in osteogenic makers.
74,168
 
Combined with increased phosphate, TNFα increases mineralization in aortic smooth 
muscle cells. We used this in vitro system to test whether PGG treatment would prevent 
osteogenic differentiation of RASMCs.  
Gene expression of several osteogenic markers, activity of alkaline phosphatase 
and proliferation of rat aortic smooth muscle cells were studied. In addition, we studied 
proliferation, alkaline phosphatase activity and calcification of osteoblasts treated with 
PGG. This was conducted in order to test the effects of PGG on osteoblasts and study any 
undesired effects on physiological bone formation. Ideally, any systemic delivery of a 
therapeutic agent to prevent arterial calcification should not affect bone physiology or 
cause extreme bone loss. Through a parallel study of aortic smooth muscle cells and 
osteoblasts, we studied the effect of PGG as a therapeutic agent for vascular calcification 
and osteoporosis. If PGG is delivered systemically, this study can give some insight into 
any potential side effects on osteoblast functioning. 
 82 
5.2. MATERIALS AND METHODS 
5.2.a Preliminary experiments 
We conducted preliminary studies to assess the optimal concentration of TNFα to 
be used in our experiments. Primary RASMCs purchased from Cell Applications Inc 
were grown at passages 8 through 10. Cells were grown in DMEM containing 10% fetal 
bovine serum and 1% penicillin-streptomycin. Media was changed every 3 days. Rat 
recombinant tumor necrosis factor-alpha (Peprotech Cat#400-14) was added to the cell 
culture media at concentrations of 0 ng/ml, 10 ng/ml, 50 ng/ml and 100 ng/ml. At the end 
of 6 days, cell lysates were collected and alkaline phosphatase activity measured as 
described in section 5.3.f. Based on the results of the preliminary experiments as 
described in section 5.4.a, the concentration of 50 ng/ml of TNFα was chosen for all 
subsequent experiments. Cell culture experiments based on these preliminary results were 
conducted as described in the sections below.  
5.2.b Cell Culture 
Primary RASMCs purchased from Cell Applications Inc were grown at passages 
8 through 10. Cells were grown in DMEM containing 10% fetal bovine serum and 1% 
penicillin-streptomycin. Media was changed every 3 days. TNFα was added to the cell 
culture media at a concentration of 50 ng/ml. PGG was added to cell culture media at a 
concentration of 10 µmol/L.  
Osteoblast cells (7F2 osteoblast cell line) were grown in alpha-MEM with 10% 
fetal bovine serum, 1% penicillin-streptomycin and 50 µg/ml ascorbic acid-2-phosphate 
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(growth media). Once confluent, growth media supplemented with 10 mmol/L β-
glycerophosphate was used to cause the osteoblasts to differentiate and deposit calcium 
phosphate. 
5.2.c Experimental groups 
TNFα and PGG were added simultaneously at day 0 and samples were collected 
at days 1, 3 and 6. The delayed group (D6) consisted of cells supplemented with TNFα at 
day 0 and PGG added at day 3 with samples collected at day 6. 
5.2.d Proliferation 
Methylthiazolyldiphenyl-tetrazolium bromide, MTT, 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (Sigma) was used to determine the 
relative proliferation rates. 5 mg of MTT was dissolved in 1ml phosphate buffered saline 
and further diluted in 9ml of DMEM. Conditioned media of cells grown for 3 days or 6 
days was aspirated and the cells rinsed carefully with phosphate buffered saline. 0.5 ml of 
the final MTT solution was added to each well and incubated at 37 C for 4 hours. At the 
end of four hours, the MTT solution was carefully aspirated and the insoluble purple 
formazan product was dissolved using 0.1% HCl in isopropanol. Absorbance was read at 
560nm and plotted as percentages of control group. 
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5.2.e Real-time PCR 
RNA was isolated from cells using the GE Illustra mini RNA isolation kit and 
quantified using the Agilent 2100 bioanalyzer. Equal amounts of RNA were reverse 
transcribed with the Applied Biosystems High Capacity reverse transcription kit. Real-
time PCR was conducted using Qiagen SYBR green master mix on a Rotorgene 3000 
PCR machine. The delta-delta Ct method was used to calculate relative gene expression 
with 18S rRNA as the housekeeping gene. 
5.2.f Alkaline phosphatase activity 
Alkaline phosphatase activity was measured using a colorimetric method that uses 
para-Nitrophenol phosphate (pNPP) as a substrate. Briefly, 5 mg of pNPP was dissolved 
in diethanolamine buffer (pH 10). Samples were combined with the pNPP solution and 
incubated at 37˚ C for 30 minutes. Alkaline phosphatase standards were also incubated 
with pNPP buffer to obtain a standard curve. The reaction caused the cleavage of 
phosphate group in pNPP and release para-Nitrophenol, a yellow soluble product. The 
absorbance for the product was measured at 405 nm and alkaline phosphatase activity 
was calculated (mU). The activities of the experimental groups were normalized to the 
control group and the percentage change was calculated. 
5.2.g Histochemical staining for alkaline phosphatase 
Visually, alkaline phosphatase activity was assessed using BCIP/NBT (5-bromo-
4-chloro-3-indolyl phosphate/ nitro blue tetrazolium) substrate (Sigma). Conditioned 
media of cells at the indicated time points were aspirated and rinsed with PBS. Equal 
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volumes of BCIP/NBT were added to the cells and incubated in the dark for 6-8 hours at 
room temperature. The BCIP/NBT solution was aspirated and cells were washed in PBS 
followed by fixation in 4% formalin-PBS solution. 
5.2.h Calcium quantification assay 
At the time points mentioned, media was aspirated and cell layers were washed 
with phosphate buffered saline (PBS). 250ul of 2N hydrochloric acid was added to each 
well, shaken for overnight at room temperature and collected by scraping the cell layers. 
O-cresolphthalein complexone assay was performed to quantify calcium and normalized 
to total protein. 
5.2.i von Kossa staining 
At the time points indicated, media was aspirated and cell layers were washed 
with PBS. The cells were then fixed in 4% Formalin-PBS for 10 minutes at room 
temperature and washed with PBS. The cells were then incubated in freshly made 5% 
silver nitrate solution in the dark for 30 minutes, washed thoroughly with DDI water and 
incubated in UV light for 1 hour for color development.   
5.2.j Alizarin red staining 
At the time points indicated, media was aspirated and cell layers were washed 
with PBS. After fixation in 4% formalin-PBS, cells were stained with 2% Alizarin red 
solution for 1 minute and excess stain was washed thoroughly with distilled deionized 
water. 
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5.2.k Data analysis 
Results are expressed as mean ± SEM with triplicates for all experimental groups. 
Statistical analysis of data was calculated using student’s t-test and probability value (p) 
was calculated and p<0.05 was considered statistically significant. 
5.3. RESULTS  
5.3.a Results of preliminary study to determine the optimal concentration of TNFα  
Increase in alkaline phosphatase (ALP) activity induced by TNFα was measured 
at day 6. As shown in Figure 5.1, 50 and 100 ng of TNFα caused similar increase in ALP, 
thus we chose to use a concentration of 50 ng/ml TNFα for our further experiments.  
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Figure 5.1: Alkaline phosphatase activity in day 6 RASMCs. * indicates significantly higher 
than the control group (p<0.05) 
5.3.b PGG inhibits increased proliferation induced by TNFα 
Cell proliferation was quantified using the MTT assay and results are shown in 
Figure 5.2. MTT assay showed increased proliferation in the TNFα groups (by almost 
50%). The addition of PGG along with TNFα inhibited the increased proliferation 
significantly. PGG alone showed reduced proliferation compared to the control group 
(Fig 5.2). Cytotoxicity test (data not shown) demonstrated that PGG is not cytotoxic to 
these cells at the concentration used. Proliferation of osteoblasts was similarly affected by 
PGG. At days 1, 3 and 6 PGG showed significant reduction in proliferation of osteoblasts 
as shown in Figure 5.3. 
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Figure 5.2: Proliferation of RASMCs as assessed by MTT assay. *indicates significantly 
different from the control group and + indicates significantly different from the TNFα 
group (p<0.05).  
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Figure 5.3: Proliferation of osteoblasts measured using MTT assay. * indicates significantly 
lower than the control group (p<0.05). 
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5.3.c PGG inhibits gene expression of osteogenic markers in RASMCs 
To understand if PGG affects the osteogenic markers at transcription level, real-
time PCR was conducted. Gene expression at days 3 and 6 indicated that PGG affected 
the mRNA levels of some osteogenic proteins (Figures 5.4A, 5.4B). Msx-2 (muscle 
segment homeobox-2) is an important transcription factor in the differentiation of 
osteoblasts. TNFα increased expression of Msx-2 by 3.3-fold which was reduced by PGG 
by almost 50% at day 3. At day 3 and 6, gene expression of CBFA-1 (core binding factor 
alpha-1) was significantly upregulated by TNFα by 2.5 and 5.4 times, respectively. Gene 
expression of alkaline phosphatase and CBFA-1 (core binding factor alpha-1) were lower 
at day 6 by PGG, but not significantly. Gene expression of osteocalcin, a marker of late 
osteogenic differentiation showed no difference between the groups at both time points. 
Alkaline phosphatase, a late gene marker of osteogenesis, was upregulated by TNFα 3.8-
fold at day 6 and was decreased by PGG 2.5 fold. 
Gene expression of transcription factors c-Jun and c-Fos, major components of 
activating protein-1 (AP-1), was measured to study the effect of PGG on cellular 
proliferation (Figures 5.5A, 5.5B). At day 3 and day 6, c-Fos expression was increased by 
TNFα by 1.8-fold and 2.2-fold respectively (p<0.05). At day 6, this increase in c-Fos 
gene expression was significantly decreased by PGG to 1.6-fold (p<0.01). This data 
demonstrated that PGG affects cellular proliferation at the transcription level.  
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Figure 5.4: Gene expression of osteogenic markers at day 3 (A) and day 6 (B). * indicates 
significantly different from the control group and + indicates significantly different from 
the TNFα group (p<0.05). 
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Figure 5.5: Gene expression of transcription factors involved in proliferation at day 3 (A) 
and day 6 (B). * indicates significantly different from the control group and + indicates 
significantly different from the TNFα group (p<0.05). 
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5.3.d PGG inhibits and reverses the increase in alkaline phosphatase activity 
induced by TNFα 
Intracellular alkaline phosphatase is an enzyme that is considered to be a 
characteristic feature of osteoblast-like cells. Observation of alkaline phosphatase activity 
in aortic smooth muscle cells is indicative of an osteogenic transdifferentiation of the 
smooth muscle cells. Determination of alkaline phosphatase activity was conducted 
quantitatively by a colorimetric assay using pNPP phosphate as substrate and 
qualitatively by using BCIP/NBT substrate. 
Alkaline phosphatase activity in cells treated with TNFα was significantly 
increased compared to control cells at days 1, 3 and 6. At all these time points, PGG 
inhibited the alkaline phosphatase activity significantly (Fig 5.6).  As shown in Figures 
5.7 and 5.8, staining for alkaline phosphatase activity also showed similar results as the 
colorimetric assay results for alkaline phosphatase. 
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Figure 5.6: Alkaline phosphatase activity in RASMCs. * indicates significantly different 
from the control group and + indicates significantly different from the TNFα group 
(p<0.05). 
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Figure 5.7: Alkaline phosphatase staining for RASMCs at day 3. Alkaline phosphatase 
activity is denoted by purple staining. Cells were treated with TNFα (A), TNFα+PGG (B), 
PGG (C) or none (D) and stained for alkaline phosphatase at day 3. (Magnification 200X) 
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Figure 5.8: Alkaline phosphatase staining for RASMCs at day 6. Alkaline phosphatase 
activity is denoted by purple staining. Cells were treated with TNFα (A), TNFα+PGG (B), 
PGG (C) or none (D) and stained for alkaline phosphatase at day 6. Purple staining 
indicates alkaline phosphatase activity. (Magnification 200X) 
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In order to determine if PGG has an inhibitory effect on alkaline phosphatase 
following TNFα treatment, cells were treated with TNFα for 3 days, then incubated for 3 
days with PGG (referred to as D6 in Materials and Methods). Alkaline phosphatase 
activity determined at day 6 is shown in Figure 5.9. Not only PGG inhibited alkaline 
phosphatase activity when added simultaneously with TNFα (Figure 5.6) but also 
reversed alkaline phosphatase activity when added 3 days following TNFα treatment. 
Staining for alkaline phosphatase also confirmed that PGG decreased alkaline 
phosphatase levels when added 3 days past TNFα treatment. 
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Figure 5.9: Alkaline phosphatase activity at day 6 in cells that were treated with 50ng/ml of 
TNFα for 3 days followed by 3 days of treatment with both TNFα and PGG. * indicates 
significantly different from the control group and + indicates significantly different from 
the TNFα group (p<0.05). 
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Figure 5.10: Staining for alkaline phosphatase activity in D6 experimental groups. Alkaline 
phosphatase activity is denoted by purple staining. RASMCs were treated with 50 ng/ml 
TNFα at day 0 (A), 50 ng/ml TNFα at day 0 followed by 10 µmol/L PGG at day 3 (B), no 
treatment at day 0 followed by 10 µmol/L PGG at day 3 (C) and no treatment at either day 
0 or day 3 (D).  
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Since alkaline phosphatase is an important enzyme in osteoblast functioning, we 
decided to investigate the effect of PGG on the activity of this enzyme in osteoblasts. As 
seen in Fig 5.11, histological staining showed that at day 6, PGG showed increased 
alkaline phosphatase activity in osteoblasts. PGG increases calcium deposition by 
osteoblasts at day 14 and day 21 as shown as seen in figures 5.12 and 5.13. 
 
  
Figure 5.11: Histological staining for alkaline phosphatase in 6 day osteoblasts. Alkaline 
phosphatase activity is denoted by purple staining. Cells treated with 10 µmol/L PGG 
(marked P) shows increased alkaline phosphatase activity compared to no treatment control 
(marked C) cells. 
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Figure 5.12: Alizarin red staining (top row) and von Kossa staining (bottom row) for 14 day 
osteoblasts. Alizarin red stains calcium deposits red and von Kossa staining causes in 
calcium deposits to color black. Cells treated with PGG (marked P) showed increased 
staining for calcium deposits relative to untreated control (marked C) cells. 
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Figure 5.13: Alizarin red staining (top row) and von Kossa staining (bottom row) for 21 day 
osteoblasts. Alizarin red stains calcium deposits red and von Kossa staining causes in 
calcium deposits to color black. Cells treated with PGG (marked P) showed increased 
staining for calcium deposits relative to untreated control (marked C) group.  
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5.3.e PGG increases calcium deposition by osteoblasts 
Calcium deposition as quantified by O’Cresolphthalein method showed that 
osteoblasts treated with PGG deposited significantly higher amount of calcium than the 
control groups at the corresponding time points. As shown in Figure 5.14, at both time 
points, PGG significantly increased mineralization by osteoblasts. 
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Figure 5.14: Quantification of calcium deposition by osteoblasts at days 14 and 21. * 
indicates significantly different from the control group (p<0.05). 
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5.4. DISCUSSION 
In this study, we show that PGG inhibits many characteristics associated with the 
transformation of vascular smooth muscle cells into osteoblast-like cells under 
inflammatory conditions. In addition, we show that PGG also helps to increase 
osteogenic characteristics such as alkaline phosphatase and mineral deposition by 
osteoblasts. It has been observed that osteoporosis, loss of mineralization from bones and 
vascular calcification, ectopic deposition of mineralization in arteries, occur often 
together.
159,160
 Thus, a therapeutic agent developed for vascular calcification should be 
designed such that it should not adversely affect the ability of bone cells to deposit or 
resorb hydroxyapatite. Bisphosphonates are a class of drugs that were developed for 
osteoporosis but are considered to have beneficial effects on atherosclerosis and vascular 
calcification; however, these benefits have not been proven. 
160,169-171
 
Studies have shown that arterial mineralization and osteoporosis occur hand in 
hand with inflammatory conditions. Inflammation triggers phenotypical changes in 
vascular smooth muscle cells as well as cause increased resorption of bone.
159,172,173
 One 
study compared the effects of oxidative stress on calcifying vascular cells and 
osteoblasts, and has suggested that oxidative stress may be a common factor between 
osteoporosis and vascular calcification.
174
 
PGG inhibited the expression of multiple genes associated osteogenesis. PGG 
showed a trend of reduced expression of many genes we studied (Figures 4A, 4B). MSX-
2, an early marker of osteoblast differentiation was upregulated at day 3 by TNFα and 
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then reduced at day 6. Msx-2 is expressed in pre-osteoblasts prior to differentiation into 
osteoblasts. Msx-2 expression is reduced during the final differentiation of osteoblasts. 
The increase in expression of Msx-2 at day 3 and its decreased expression at day 6 
indicates the transformation of the smooth muscle cells into osteoblast-like cells similar 
to osteoblast differentiation in bone. PGG inhibited the over-expression of MSX-2 at day 
3 so PGG may inhibit the early markers of osteoblast differentiation in smooth muscle 
cells. 
In rat aortic smooth muscle cells, PGG significantly decreased the activity of 
alkaline phosphatase, an enzyme considered to be important in the osteoblast mediated 
deposition of calcium phosphate (Figures 5.6-5.10). In contrast, alkaline phosphatase 
activity and mineralization were increased by PGG in osteoblasts as shown in Figures 
5.11-5.13. 
PGG exerted similar effects on the proliferation of both vascular smooth muscle 
cells and osteoblasts. This could be an important factor in explaining the contrasting 
effects of PGG on the two types of cells we studied. We hypothesize that PGG inhibits 
cells from multiplying and causes the cells to remain in a differentiated state. It has been 
shown that aortic smooth muscle cells do not exist in a finally differentiated state and are 
more flexible to proliferate and deposit extracellular matrix in case of injury or 
inflammation.
105,175
 PGG may therefore prevent the dedifferentiation of vascular smooth 
muscle cells into osteoblastic lineage and allow the cells to function as smooth muscle 
cells. In the case of osteoblasts, PGG may allow the cells to remain in their differentiated 
state and promote their function of depositing calcium apatite. The transcription factors c-
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Fos and c-Jun are members of the AP-1 family. AP-1 is the product of dimerization 
between c-Fos and c-Jun or between c-Jun and c-Jun. AP-1 binds to the enhancer region 
of target genes and regulates the transcription of genes associated with proliferation. 
Correlation between the expressions of c-Fos and c-Jun is an important factor in 
regulating the pathways of proliferation and growth.
176-179
 Other studies have shown that 
some polyphenolic compounds including epigallocatechin and curcumin inhibit the cell 
cycle progression and AP-1 activity in vascular cells.
180-182
 Therefore, we investigated the 
gene expression of c-Fos and c-Jun in our experiments. Our results show that c-Jun gene 
expression was unaffected in all the groups at both days 3 and 6, compared to the control 
(Figures 5.5A, 5.5B). However, TNFα increased the expression of c-Fos significantly at 
days 3 & 6. PGG decreased the expression of c-Fos at both day 3 (p>0.05) and day 6 
(p<0.05) when combined with TNFα. PGG alone also showed significantly decreased 
expression compared to control at day 6. These results could indicate that PGG could 
influence the cell cycle and affect the pathways of growth and DNA replication. 
The exact mechanism by which PGG causes the above mentioned effects is not 
understood. Further studies to assess the expression of transcription factors involved in 
cell cycle progression and dedifferentiation of vascular smooth muscle cells such as 
GATA-6 could reveal more specifics of the actions of PGG. We believe that this is the 
first study that shows the reversal of osteogenic properties (alkaline phosphatase activity) 
in smooth muscle cells. More studies need to be conducted to better understand the 
effects and possible side effects of PGG. 
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CHAPTER 6  
TO PREPARE AND CHARACTERIZE POLY(LACTIC-CO-GLYCOLIC) ACID 
NANOPARTICLES ENCAPSULATING PENTAGALLOYLGLUCOSE TO BE 
POTENTIALLY USED FOR IN VIVO DELIVERY OF 
PENTAGALLOYLGLUCOSE  
6.1. INTRODUCTION 
From the studies discussed above, we conclude that PGG could be a valuable 
therapeutic agent due to its various beneficial effects in vascular diseases. As shown in 
the preceding results, PGG inhibits proliferation due to inflammatory conditions, 
effectively controls the activity of proteolytic enzymes, and down regulates osteogenic 
signaling in rat aortic smooth muscle cells. In parallel, PGG demonstrated positive effects 
on osteoblast function. Thus, PGG can have positive effects in cardiovascular pathologies 
and bone mineralization if delivered locally. In this study, we studied PGG encapsulated 
nanoparticles as a potential mode of PGG in vivo. 
Nanoparticles with a size range of 10-1000 nm are frequently used for drug 
delivery applications. Drugs or DNA can be entrapped, dissolved, encapsulated or 
attached to nanoparticles. The advantages of nanoparticles include high surface area to 
volume ratio, controlled degradation time, and storage stability. Disadvantages of 
nanoparticles include particle aggregation, limited drug loading and optimized drug 
release.
183
 We wanted to test the possibility of preparing PGG loaded nanoparticles and 
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studied the release profile of these nanoparticles. Poly-(lactic-co-glycolic) acid (PLGA) 
nanoparticles encapsulating pentagalloylglucose (PGG) were prepared as ‘proof of 
concept’. 
6.2. MATERIALS AND METHODS 
6.2.a PLGA nanoparticle synthesis 
Two hundred milligrams of PLGA was dissolved in 12 ml of dichloromethane. 
Ten ml of aqueous PGG solution (500 µg/ml) was sonicated with the PLGA (1
st
 
sonication) to obtain a water-in-oil (W/O) emulsion. This emulsion was diluted in 50 ml 
of 1.5% polyvinyl alcohol (PVA) and further sonicated (2
nd
 sonication) to obtain a water-
in-oil-in-water (W/O/W) emulsion.  Various sonication times were used as shown in 
Tables6.1 and 6.4. The resultant W/O/W emulsion was stirred under a fume hood 
overnight to obtain PGG encapsulated nanoparticles. The nanoparticles were centrifuged 
at 30,000g. The resultant pellet was washed twice with distilled water, and centrifuged at 
30,000g between washes. The pellet was frozen at -80 
o
C and lyophilized.  
6.2.b Measurement of nanoparticles size 
The lyophilized nanoparticles (1 mg) was resuspended in water and analyzed with 
particle analyzer. Lyophilized particles were imaged with scanning electron microscope 
(Hitachi S4800). 
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6.2.c Encapsulation efficiency 
The lyophilized nanoparticles (5 mg) were sonicated on ice for 1 hour and 
analyzed for encapsulation efficiency by measuring the absorbance of PGG at 245nm 
against a PGG standard curve. 
6.2.d In vitro release profile 
Release profile of the nanoparticles was conducted in vitro to test the amount of 
PGG released over time. Ten mg of nanoparticles were added to 5 ml of PBS (pH 7.4) 
and shaken at 37 ˚C for 48 hours. Samples were collected at indicated time points after 
centrifugation. PGG released was measure by UV absorbance at 245 nm with blank 
nanoparticle release used as blank readings. 
6.3. RESULTS 
We were able to successfully prepare PLGA nanoparticles encapsulating PGG. 
Measurement of nanoparticles size using particle analyzer (Table 6.2) and scanning 
electron microscope (Figure 6.1) showed that the nanoparticle diameters were within the 
range of 250-300 nm. The polydispersity increased when the W/O/W sonication time was 
increased. However, W/O/W sonication of more than 3 minutes decreased the 
polydispersity as displayed in Table 6.2. Increase in sonication times lead to decreased 
encapsulation efficiency of PGG as shown 6.3. 
Release profile of the nanoparticles prepared as shown in Table 6.4 showed a 
linear release profile and released about 97% of encapsulated PGG over 48 hours as 
shown in Figure 6.2.  
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Sample # 
 
W/O sonication 
time 
W/O/W sonication 
time 
1 2 min 1 min 
2 3 min 2 min 
3 3 min 3 min 
4 3 min 5 min 
Table 6.1: Nanoparticles were synthesized using different combinations of sonication times 
Sample # Diameter Polydispersity 
1 295 0.133 
2 396 0.162 
3 236 0.174 
4 267 0.129 
Table 6.2: Diameter and polydispersity of nanoparticles  measured with a particle analyzer. 
Nanoparticles were prepared with sonication times shown in Table 6.1 
Sample # 
PGG (µg) in 5mg 
nanoparticles 
PGG (µg) in 5mg 
nanoparticles 
Average 
% loading of PGG 
1 610 423 12.2% 
2 473 396 9.46% 
3 366 402 7.32% 
4 238 248 4.76% 
Table 6.3: Encapsulation efficiency of PGG-PLGA nanoparticles prepared with sonication 
times shown in Table 6.1 
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Figure 6.1: Scanning electron microscope images of PGG encapsulated PLGA nanoparticles 
prepared with sonication times shown in Table 6.1 
Sample # W/O sonication time W/O/W sonication time 
A 45 sec 30 sec 
B 30 sec 30 sec 
Table 6.4: Nanoparticles were synthesized again with indicated sonication times for W/O 
and W/O/W emulsions  
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Sample # 
Initial weight of 
nanoparticles (mg) 
µg of PGG % loading of PGG 
A 4.32 510 11.81% 
B 4.21 498 11.83% 
Table 6.5: Percentage loading of nanoparticles prepared with sonication times shown in 
Table 6.4 
 
Figure 6.2: Release profile of PGG from nanoparticles prepared with sonication times 
shown in Table 6.4 
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6.4. DISCUSSION 
We have demonstrated that PGG can indeed be encapsulated into PLGA 
nanoparticles. Variation in sonication times during W/O and W/O/W emulsions can 
affect the size and loading of the nanoparticles as seen in Tables 6.2 and 6.3. In vitro 
release profile of nanoparticles prepared as shown in Table 6.4 released almost 97% of 
PGG within 48 hours. Further optimization of loading and sonication times is needed to 
prepare PGG nanoparticles that have longer release times.  
Release of PGG from nanoparticles may differ significantly in vivo from in vitro 
release. The in vivo therapeutic effects of PGG could be affected due to acidification of 
the local area (of delivery) caused by the release of lactic acid, a product of PLGA 
degradation. Studies need to be conducted in order to verify that the change in pH will 
not adversely affect the beneficial effects of PGG. Further optimization is necessary to 
design nanoparticles with the required size, encapsulation efficiency and release profile 
for in vivo delivery.  
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CHAPTER 7  
IMPLEMENTATION AND PRELIMINARY CHARACTERIZATION OF A NEW 
IN VITRO MODEL OF MEDIAL VASCULAR CALCIFICATION USING CRYO-
SECTIONED ARTERIAL SCAFFOLDS 
7.1. INTRODUCTION 
Cell-matrix interactions are an important aspect of cell behavior and function. 
Some proteins such as collagen and laminin can be easily coated on the bottom of well 
plates. Interactions between cells and collagen or laminin can be studied by growing cells 
on these substrates. Commercially available well plates with their proteins coated on 
them are easily available. Coating proteins such as collagen and laminin is a fairly 
straightforward procedure involving solubilizing the protein, coating the bottom of the 
well plate uniformly with the solubilized protein, letting it dry and hydrating it before 
seeding cells. 
Medial vascular calcification involves mineralization of elastic fibers and 
transformation of vascular smooth muscle cells into osteoblast-like cells. Interactions 
between vascular smooth muscle cells and their native environment are important to 
understand so that we can better comprehend the factors involved in vascular 
calcification. However, currently there are no established methods to simulate the 
interactions between elastic fibers and smooth muscle cells in vitro mainly because 
elastic fibers cannot be solubilized and coated on culture plates. 
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The following method describes a procedure by which arterial cryo-sections can be 
prepared so that interactions between the medial extracellular matrix proteins and cells 
can be studied in vitro. The arterial sections can also be processed to remove specific 
proteins and create a controlled extracellular matrix substrate. 
7.2. MATERIALS AND METHODS 
7.2.a Preparation of scaffolds 
Fresh porcine thoracic aortae (obtained from a local slaughterhouse) were rinsed 
with distilled water and cut along the longitudinal axis to obtain a rectangular piece of 
aorta. These were cut into smaller rectangles so that the tissue section covered the bottom 
of a well in a 24-well plate. These smaller rectangles were then embedded with OCT 
(optimal cutting temperature compound) with the luminal side down and frozen at -20 
o
C 
until sectioned. The embedded aortae were then sectioned to obtain flat sections 
(perpendicular to the normal cross sections) of 20 microns thickness. These were placed 
on the bottom of 24 well plates.  
7.2.b Decellularization 
The scaffolds were washed with distilled de-ionized water for 15 minutes to 
remove the water soluble OCT compound followed by decellularization. 
Decellularization was performed by incubation in 0.1% sodium dodecyl sulfate (SDS) in 
PBS for 20 minutes, followed by rinsing with sterile PBS thrice.  
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7.2.c Scaffold characterization 
Cleaned and decellularized scaffolds were fixed with 4% formalin/PBS solution 
for 10 minutes and stained with routine Hematoxylin and Eosin (H&E) staining to detect 
the presence of cells or cell debris.  
7.2.d Seeding cells  
Once decellularized and rinsed thoroughly, the scaffolds were incubated in 70% 
ethanol for 15 minutes to sterilize them. The scaffolds were then rinsed thrice with sterile 
PBS thrice and incubated with DMEM containing 10% FBS and 1% penicillin 
streptomycin for 15 minutes before seeding cells.  
7.2.e Cell culture experiments 
Primary RASMCs were seeded onto these scaffolds and onto untreated tissue 
culture well plates without scaffolds (referred to as tissue culture polystyrene or TCPS). 
The cells were allowed to attach for 24 hours before treatment. The treatments were 
TNFα (10 ng/ml), Pi (2 mmol/L) + Ca (4 mmol/L), TNFα (10 ng/ml) + Pi (2 mmol/L) + 
Ca (4 mmol/L), untreated (control). Media was changed at day 3 along with 
corresponding treatments. At the end of day 7, cells were rinsed with PBS and fixed with 
4% formalin/PBS for 10 minutes and stained for calcium using silver nitrate (Von Kossa 
method). Samples for calcium quantification were collected with 0.5 mol/L hydrochloric 
acid and calcium deposition quantified using O-cresolphthalein-complexone method.  
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7.3. RESULTS 
7.3.a Decellularization 
Decellularization efficiency was assessed by H&E staining which stains nuclei 
blue. Scaffold decellularization using 0.1% SDS-PBS showed incomplete removal of 
cellular material from scaffolds. However, using sodium hydroxide resulted in complete 
decellularization and removal of collagen, leaving behind pure elastin scaffolds (Fig 8-1). 
Ideally, the 20µm thick sections should be incubated in 0.1mol/L sodium hydroxide for at 
least 5 hours to achieve complete decellularization and removal of collagen (Fig 8-2). 
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Figure 7.1: Decellularization of scaffolds using 0.1% SDS-PBS solution 
  
  
Figure 7.2: Decellularization and removal of all extracellular matrix proteins except elastin 
form the scaffolds using 0.1 mol/L sodium hydroxide 
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7.3.b Calcium deposition was higher in cells grown on arterial scaffolds 
When RASMCs were grown on TCPS or arterial scaffolds for 7 days with 
treatment groups as described above, it was observed that cells seeded on scaffolds 
deposited increased calcium than the TCPS counterpart (Figure 7.3). This difference was 
statistically significant between the cells treated with TNFα+Pi+Ca on arterial scaffold 
and cells treated with TNFα+Pi+Ca on untreated tissue culture well plates (Fig 7.4). 
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Figure 7.3: von Kossa staining for RASMCs seeded on arterial scaffolds (A-D) or untreated 
tissue culture well plates (E-H). A and E -  Control (no treatment), B and F – 10 ng/ml 
TNFα, C and G – 10 ng/ml TNFα + 2 mmol/L Pi + 4 mmol/L Ca.
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Figure 7.4: Influence of arterial scaffolds on RASMC calcification  
 
7.3.c Gelatin zymography  
Cells grown on arterial scaffold had increased MMP-2 and MMP-9 activities 
compared to their corresponding TCPS groups (Figure 7.5). Interestingly, MMP-2 
activity in the conditioned media of cells treated with increased calcium and phosphate 
showed lower activity than the control (untreated) group. However, this was a pilot study 
and the experiment needs to be repeated with more samples in order to obtain statistically 
relevant results. 
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Figure 7.5: Gelatin zymography to detect MMPs in day 7 conditioned media  
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7.4. DISCUSSION 
Studying the influence of elastic fibers on the behavior of aortic smooth muscle 
cells is important to understand many factors involved in arterial calcification and 
aneurysms. The model described here provides a simple, inexpensive and effective way 
to simulate the medial layer of arteries in vitro. Vascular medial calcification involves 
accumulation of calcium phosphate in the elastic fibers and this model helps to simulate 
this condition in vitro. This model can be used in conjunction with existing models of 
pathological conditions such as addition of cytokines to gain a deeper understanding of 
the smooth muscle cell responses. 
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CHAPTER 8  
CONCLUSIONS AND RECOMMENDATIONS 
8.1. CONCLUSIONS 
Atherosclerosis, vascular calcification and aneurysms share some common 
pathological conditions such as excess proteolytic activity, increased proliferation and 
migration of aortic smooth muscle cells. Arterial calcification also involves the 
morphological transformation of aortic smooth muscle cells into osteoblast-like cells. 
Reversing these pathological conditions can help to control or even reverse these vascular 
diseases. However, current treatments for vascular diseases are very limited. We 
investigated pentagalloylglucose (PGG) as a therapeutic agent that inhibits many 
characteristics of vascular diseases using an in vitro model. We were able to arrive at the 
following conclusions: 
(1) PGG inhibits the release of excess proteolytic enzymes specifically MMP-
2, cathepsins K, L and S 
(2) PGG inhibits the differentiation of rat aortic smooth muscle cells into 
osteoblast-like cells 
(3) PGG increases the release of tropoelastin and deposition of insoluble 
elastin by primary rat aortic smooth muscle cells 
(4) PLGA nanoparticles encapsulating PGG can be prepared and potentially 
used to deliver PGG in vivo 
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8.2. RECOMMENDATIONS 
Based on our experimental results, the following studies are recommended for 
future work: 
A) Examine the effects of PGG on in vivo models of vascular diseases. Studies 
should be conducted to optimize the dosage of PGG to be delivered 
systemically or orally. Hypercholesterolemic and ApoE knockout mice could 
be used as a model for atherosclerosis. Warfarin and vitamin K treated mice 
can simulate chronic kidney disease associated vascular calcification. 
Aneurysmal model can be simulated by using the elastase perfusion method. 
Optimized PGG doses can be delivered to study if PGG can have beneficial 
effects in vivo.  
B) Use PGG treated primary rat aortic smooth muscle cells to deposit insoluble 
elastin in tissue engineered scaffolds to use as vascular grafts. From our 
results, PGG has shown promise in the in vitro generation of insoluble elastin. 
Electron microscopy and immunostaining should be conducted to further 
characterize the insoluble elastin produced by RASMCs in vitro. Creating 
tissue engineered grafts that contain elastin could be beneficial in many ways 
including better mechanical and structural properties. Synthetic polymeric 
scaffolds or naturally derived, decellularized vein scaffolds could be used. 
Mechanical testing and elastase degradation could be used to test these grafts 
in vitro. 
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C) Use cryo-sectioned arterial scaffolds to study medial calcification in vitro. 
Aortic smooth muscle cells seeded on the arterial scaffolds described in 
chapter 8 can be induced to calcify using existing in vitro models of vascular 
calcification. The scaffold could provide a simulation of medial arterial layer 
and provide the extracellular matrix to simulate a more physiologically 
relevant condition. 
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